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Resumo 
 
A doença de Alzheimer (AD) é a forma mais comum de demência, constituindo 
um problema de saúde pública grave, devido ao aumento da esperança média de vida 
da população mundial, bem como ao longo período de progressão desta doença 
incapacitante.  A AD é caracterizada, em termos patológicos, por acumulação de 
péptido amilóide-β (Aβ), a nível extracelular e de tranças neurofibrilares intraneuronais, 
compostas por agregados de proteína tau hiperfosforilada, em regiões cerebrais 
específicas.  A neuroinflamação crónica e a perda progressiva de neurónios, sinapses 
e matéria branca são características adicionais que também estão associadas à 
doença. 
O ácido tauroursodesoxicólico (TUDCA) é um ácido biliar endógeno, anti-
apoptótico, capaz de atravessar a barreira hematoencefálica e que apresenta fortes 
propriedades neuroprotectoras, em diversos modelos experimentais de AD.  
Resultados obtidos anteriormente pelo nosso grupo demonstraram a eficácia 
terapêutica do TUDCA em murganhos duplamente transgénicos APP/PS1, antes de 
estes apresentarem deposição de placas amilóides.  Neste estudo, o tratamento 
preventivo com TUDCA resultou, não só na diminuição da produção e acumulação de 
Aβ, como também na redução da activação da resposta glial face à acumulação de 
agregados amilóides.  É de salientar que o tratamento com TUDCA conduziu a 
melhorias na memória dos animais, o que poderá estar relacionado com a diminuição 
da perda de sinapses, também observada. 
No estudo agora apresentado, pretendeu-se avaliar os efeitos protetores do 
TUDCA, quando administrado após o desenvolvimento da patologia amilóide no 
mesmo modelo transgénico de AD. Os murganhos APP/PS1 com 7 meses de idade 
foram injetados intraperitonealmente com TUDCA (500 mg/kg), a cada 3 dias, durante 
3 meses.  Após a realização do teste aquático de Morris, destinado à avaliação da 
memória espacial dos murganhos, os animais foram sacrificados e um dos hemisférios 
cerebrais foi processado para análise imunohistoquímica (IHC). O outro hemisfério foi 
preservado para isolamento do hipocampo e córtex frontal e posterior extração de 
RNA e proteínas. 
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O tratamento com TUDCA levou a uma diminuição significativa da deposição 
de Aβ em ambas as regiões cerebrais analisadas, com uma maior redução detetada 
no hipocampo.  Esta observação explica-se, provavelmente, pelo facto de neste 
modelo transgénico, o hipocampo apresentar placas amilóides apenas a partir dos 2-3 
meses, enquanto que o neocórtex apresenta depósitos de Aβ logo a partir das 6 
semanas.  Contudo, ensaios de ELISA confirmaram que os níveis de Aβ40 e Aβ42 
estavam significativamente diminuídos em ambas as regiões, após o tratamento com 
TUDCA.  Estes resultados estão de acordo com a diminuição do processamento 
amiloidogénico da proteína precursora do Aβ (APP) observada no córtex e hipocampo, 
e sugerem que o tratamento com TUDCA interfere na produção de Aβ. 
Avaliaram-se também os níveis de fosforilação de resíduos específicos da 
proteína cinase B, ou Akt, e da cinase da glicogénio sintase 3β (GSK3β), que se 
relacionam indiretamente com os seus níveis de atividade.  A enzima Akt, quando 
ativa, encontra-se fosforilada no resíduo de serina 473, podendo então fosforilar a 
GSK3β na serina 9, o que inibe a atividade desta.  É de salientar que o eixo 
Akt/GSK3β se encontra desregulado na AD.  A enzima Akt é alvo da via controlada 
pela fosfatidilinositol-3-cinase (PI3K), estando ambas envolvidas na ativação de 
mecanismos de sobrevivência neuronal e de potenciação sinática.  A GSK3β encontra-
se amplamente descrita como estando hiperativada na AD, ,parecendo envolvida em 
inúmeros processos associados à progressão da doença.  Por exemplo, a GSK3β é 
uma das principais enzimas responsáveis pela fosforilação de vários resíduos da 
proteína tau, pelo que a sua desregulação se encontra associada à hiperfosforilação 
da tau.  Mais ainda, a GSK3β tem a capacidade de fosforilar a APP num resíduo 
citoplasmático, o que pode contribuir para a produção de Aβ.  Curiosamente, a inibição 
da atividade desta cinase parece diminuir a expressão da β-secretase (BACE1), 
reduzindo o processamento amiloidogénico da APP e, consequente, a produção de 
Aβ. A GSK3β surgiu recentemente como um mediador-chave da ativação microglial e 
astroglial em condições inflamatórias, incluindo na AD.  Neste sentido, a inibição desta 
cinase in vivo tem o potencial de melhorar significativamente as patologias associadas 
à AD. 
Como seria de esperar, a análise por Western blot (WB) revelou uma 
diminuição dos níveis de fosforilação da Akt e da GSK3β no córtex, bem como uma 
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diminuição nos níveis de fosforilação da GSK3β no hipocampo de murganhos 
APP/PS1.  Em contrapartida, os animais transgénicos tratados com TUDCA 
apresentaram níveis de fosforilação destas enzimas semelhantes aos detetados nos 
murganhos controlo, o que sugere que o TUDCA normaliza os níveis de atividade 
destas enzimas, no contexto da AD.  Os níveis de fosforilação do resíduo de 
serina 396 da proteína tau, que se encontram aumentados nos murganhos APP/PS1, 
foram igualmente diminuídos pelo tratamento com TUDCA.  Como este resíduo é um 
alvo importante da GSK3β, a diminuição dos seus níveis de fosforilação poderão 
indicar a reposição da atividade da GSK3β pelo TUDCA.  Verificou-se ainda que, ao 
contrário do esperado, o tratamento com TUDCA não afetou o nível de fosforilação da 
APP e a quantidade de BACE1 presente nos cérebros dos murganhos transgénicos 
tratados, face ao observado nos murganhos transgénicos não tratados, indicando que 
a atividade desregulada da GSK3β não modula estas vias neste modelo animal, ou 
que outros mecanismos moleculares poderão estar envolvidos. 
Neste estudo, e à semelhança de outros anteriores, o tratamento com TUDCA 
atenuou significativamente a ativação pro-inflamatória dos astrócitos e da microglia em 
redor das placas amilóides.  De igual modo, o tratamento com TUDCA conduziu a uma 
diminuição significativa dos níveis de mRNA do factor de necrose tumoral α (TNFα), 
uma das citocinas pro-inflamatórias aumentadas na AD e envolvidas na progressão da 
doença. 
Relativamente ao conteúdo sinático, detetou-se uma diminuição nos níveis da 
proteína sinaptofisina no giro denteado do hipocampo de murganhos APP/PS1, que se 
correlaciona com a disfunção destas estruturas e a desregulação neurológica 
generalizada.  Esta redução foi parcialmente revertida nos animais tratados com 
TUDCA, podendo dever-se ao aumento de atividade da cinase Akt que se encontra 
envolvida na potenciação da resposta sinática ou, simplesmente, à diminuição dos 
níveis de Aβ. Contudo, os estudos comportamentais permitiram concluir que o 
tratamento tardio com TUDCA, apesar de melhorar alguns aspetos da patologia, ao 
nível molecular, não melhora significativamente a perda de memória espacial dos 
murganhos APP/PS1, tendo-se observado apenas uma tendência para tal.  Esta 
observação poderá advir do facto destes animais já manifestarem défices de memória 
desde os 7 meses de idade, altura em que se iniciou o tratamento com TUDCA.  
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Em conclusão, os resultados obtidos neste trabalho demonstraram a eficácia 
terapêutica do TUDCA quando administrado a murganhos APP/PS1 já com 
características patológicas associadas à AD. O TUDCA atenua a produção e 
deposição de Aβ, a hiperfosforilação da proteína tau, a activação glial e a perda de 
integridade sináptica, sendo que vários destes efeitos poderão dever-se, 
especificamente, à modulação da via Akt/GSK3β. Estes dados sugerem que a 
utilização do TUDCA não reverte as condições patológicas associadas à perda de 
memória emergentes ou já existentes na AD sendo, no entanto, uma estratégia 
terapêutica promissora para atenuar ou retardar a progressão da doença. 
 
Palavras-chave: Amilóide-β; Cinase da glicogénio sintase 3β; Murganho 
APP/PS1; Neuroinflamação; Proteína precursora do amilóide- β; Tau; TUDCA 
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Abstract 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder hallmarked by the 
accumulation of extracellular amyloid-β (Aβ) peptide and intraneuronal neurofibrillary 
tangles composed of hyperphosphorylated tau, as well as chronic neuroinflammation 
and loss of neurons, synapses and white matter.  Tauroursodeoxycholic acid (TUDCA) 
is an endogenous anti-apoptotic bile acid with potent neuroprotective properties in 
several experimental models of AD.  We have previously reported the therapeutic 
efficacy of TUDCA treatment before amyloid plaque deposition in APP/PS1 double-
transgenic mice.  Importantly, preventive treatment with TUDCA not only reduced Aβ 
generation and accumulation, while reducing gliosis, but also ameliorated memory 
deficits and protected against synaptic loss. 
In the present study, we evaluated the protective effects of TUDCA when 
administrated after the onset of amyloid pathology.  APP/PS1 transgenic mice with 7 
months of age were injected intraperitoneally with TUDCA (500 mg/kg) every 3 days, 
for 3 months. TUDCA treatment significantly attenuated Aβ deposition in the brain, with 
a concomitant decrease in Aβ40 and Aβ42 levels.  The amyloidogenic processing of the 
amyloid precursor protein was also reduced, indicating that TUDCA interferes with Aβ 
production.  In addition, TUDCA abrogated GSK3β hyperactivity, which is highly 
implicated in tau hyperphosphorylation and glial activation.  This effect was likely 
dependent on the specific activation of the upstream kinase, Akt. TUDCA treatment 
also reduced microglial and astroglial activation, and tumor necrosis factor α (TNFα) 
expression levels.  Finally, TUDCA treatment partially rescued synaptic loss in the 
dentate gyrus of the hippocampus.  Overall, our results suggest that TUDCA is a 
promising therapeutic strategy not only for the prevention but also for the treatment of 
AD after disease onset. 
 
Keywords: Amyloid-β; Amyloid precursor protein; APP/PS1 mice; Glycogen 
synthase kinase β; Neuroinflammation; Tau; TUDCA 
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Dementia is nowadays a major public health problem, since overall life 
expectancy has greatly increased. Worldwide, dementia was estimated to affect more 
than 35.6 million individuals in 2010, and is expected to double in the next 20 years 
(Prince et al., 2013).  Alzheimer’s disease (AD) accounts for approximately 70% of the 
cases associated with dementia, thus being the most common manifestation of this 
type of pathology (Reitz and Mayeux, 2014).  
 
1. Alzheimer’s Disease 
Symptomatically, AD is initially manifested as a progressive loss of episodic 
memory – termed mild cognitive impairment (MCI) – that slowly progresses toward full 
dementia, characterized by extensive memory deterioration, cognitive impairment and 
abnormal behavior (Selkoe, 2001; Reitz and Mayeux, 2014).  AD is a disabling, slow 
progressing disease, usually developing over the course of decades. Consequently, 
AD patients become highly demanding cases on healthcare and social services, with a 
huge impact in the countries’ economies (Reitz and Mayeux, 2014).   
At early stages of AD, the main affected brain areas are the cholinergic basal 
forebrain and medial temporal lobe structures, including the hippocampus and 
entorhinal cortex.  With disease progression, several cortical regions become also 
affected (Braak and Braak, 1991). 
Pathologically, AD is hallmarked by the presence of extracellular senile plaques 
(SPs) composed of amyloid-β (Aβ) peptide aggregates, intraneuronal neurofibrillary 
tangles (NFT) composed of hyperphosphorylated tau protein, chronic 
neuroinflammation and loss of neurons, synapses and white matter (Fig. 1) (Selkoe, 
2001).  Since AD is the most common form of dementia, the etiology and pathology 
mechanisms of this devastating disease have been intensively investigated after its 
discovery, in 1906 (Selkoe, 2001).  However, the triggering mechanisms of AD are far 
from fully deciphered, and effective diagnosis and treatment are still highly demanded. 
 
1.1. Epidemiology and risk factors 
Advanced age is the most pronounced risk factor for AD, with the prevalence of 
the disease increasing substantially between the 65 and 85 years of age, so that AD 
affects 30–50% of all people with 85 years (Isik, 2010; Reitz and Mayeux, 2014).   
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Fig. 1.  Neuropathological hallmarks of Alzheimer’s disease.  (A, B) Silver staining 
for extracellular amyloid plaques (yellow arrows) (A) and intraneuronal neurofibrillary tangles (B) 
in brain sections from an AD patient.  (C) Immunohistochemical staining of a plaque composed 
of Aβ (green), presenting infiltrating filaments from microglia, here stained with an anti-Iba-I 
antibody (red).  Scale bar, 40 μm.  Adapted from O’Brien and Wong, 2011. 
 
Based on the age of onset, the disease can be classified as early onset AD 
(EOAD), if it occurs before 65 years of age, and late onset AD (LOAD), after 65 years 
(Isik, 2010). 
EOAD, which is clinically indistinguishable from LOAD, accounts for 1-5% of all 
cases and is usually inherited in an autosomal dominant manner, being therefore 
termed familial AD.  EOAD results from mutations in three different genes, the amyloid 
precursor protein (APP) gene and the presenilin 1 (PS1) and presenilin 2 (PS2) genes, 
with mutations in the PS1 gene accounting for most of the cases (Selkoe, 2001; Reitz 
and Mayeux, 2014). 
LOAD typically correlates with sporadic forms of AD, and its causative factors 
are still unclear.  Like most chronic diseases, AD appears to be a multifactorial disease.  
Epidemiological studies have reported several possible risk factors that can be 
associated with LOAD etiology.  These include limited intellectual and cognitively 
stimulating activities at both young and old ages, low levels of education and 
occupation, lack of physical exercise during late life, cerebrovascular diseases, 
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traumatic brain injuries, hypo- and hypertension, diabetes and obesity (Reitz and 
Mayeux, 2014). 
Although environmental factors may alter the susceptibility to LOAD, several 
genome-wide association studies (GWAS) have implicated putative genetic factors that 
contribute to the onset of LOAD (Reitz and Mayeux, 2014), including the presence of 
the ε4 allele of apolipoprotein E (APOE) gene.  The protein encoded by this allele 
appears to be structurally altered, which results in deregulated brain lipid metabolism 
and abnormal interaction of ApoE with Aβ peptides, leading to reduced Aβ clearance 
and enhanced Aβ aggregation (Bu, 2009).  Several other loci have been proposed to 
influence the susceptibility to AD based on GWAS studies.  Curiously, the vast majority 
are clustered in four main pathways, namely immune response, APP processing, lipid 
metabolism, and endocytosis (Reitz and Mayeux, 2014). 
 
1.2. Pathogenesis 
The long pre-clinical phase of AD encompasses several pathologic mechanisms 
in specific brain regions that primarily lead to synaptic loss, the first culprit involved in 
memory and cognitive deficits in AD patients, followed by neurodegeneration and 
development of SPs and NFTs, the histopathological features of AD (Selkoe, 2001; 
Walsh and Selkoe, 2007; Perrin et al., 2009).  These pathological mechanisms involve 
ROS production, mitochondrial failure, deregulation of Ca2+ metabolism, inflammation 
and neuronal dysfunction (Cavallucci et al., 2012). 
 
1.2.1. Amyloid cascade hypothesis 
Aβ peptides are the principal constituents of SPs found in AD brains (Selkoe, 
2001).  Aβ derives from the sequential proteolysis of APP, a single-pass 
transmembrane glycoprotein with a large extracellular domain (O'Brien and Wong, 
2011; Haass et al., 2012).  Depending on its subcellular location, APP can be 
preferably cleaved through the amyloidogenic or anti-amyloidogenic pathways (Fig. 2) 
(O'Brien and Wong, 2011; Haass et al., 2012). 
In the amyloidogenic pathway, APP processing is mainly catalyzed by the 
canonical β-secretase beta-site APP cleaving enzyme 1 (BACE1), a transmembrane 
aspartic protease that presents optimal activity in slightly acidic compartments, such as 
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endocytic vesicles and endosomes.  Cleavage of APP by β-secretase leads to the 
shedding of its large ectodomain (termed soluble APP-β fragment, or sAPP-β) and the 
production of a small membrane-spanning C-terminal fragment β (CTF-β).  CTF-β is 
further cleaved by γ-secretase in the transmembrane domain, generating Aβ and 
releasing the C-terminal fragment γ (CTF-γ) into the cytoplasm (O'Brien and Wong, 
2011; Haass et al., 2012). 
Alternatively, APP can be processed by α-secretase activity, catalyzed by the 
ADAM (a disintegrin and metalloproteinase) family of proteases that occurs mainly on 
the cellular membrane and generates soluble sAPPα and APP C-terminal fragment α 
(CTF-α).  The α-secretase cleavage site is located within the Aβ region, thus precluding 
BACE1 cleavage and Aβ production.  Finally, cleavage by γ-secretase releases CTF-γ 
and a truncated Aβ peptide termed p3, which apparently does not have any biological 
relevance.  Importantly, γ-secretase can cleave CTFs by performing sequential series 
of intramembranous cuts, thus yielding Aβ peptides with approximately 4 kDa and 
lengths that range from 38 to 43 amino acids.  The most common form of Aβ contains 
40 amino acids (Aβ40), while the most toxic contains 42 amino acids in length (Aβ42) 
(Selkoe, 2001; O'Brien and Wong, 2011; Haass et al., 2012). 
Curiously, Aβ production occurs constitutively in the brain throughout life, and 
the peptide is suggested to have physiological roles at very low concentrations.  In fact, 
Aβ potentiates hippocampal long-term potentiation (LTP) at picomolar concentrations 
(Puzzo et al., 2008).  Moreover, Aβ is also suggested to possess limited antioxidant 
activities due to its ability to chelate redox metal ions (Atwood et al., 2003).  Finally, Aβ 
appears to present neurotrophic properties under deprived conditions (Fonseca et al., 
2013). 
Conversely, at supraphysiological concentrations, Aβ self-aggregates into 
higher order structures.  Initially, soluble Aβ acquires higher β-sheet content, leading to 
self-dimerization/trimerization, which is followed by oligomerization into soluble high 
molecular aggregates forming spherical oligomers, protofibril formation and finally 
aggregation into insoluble fibrillar structures characteristic of SPs (Serpell, 2000; Kayed 
and Lasagna-Reeves, 2013).  Importantly, mounting evidence indicates that increases 
in the ratio Aβ42/Aβ40 within the brain is predictive of AD progression, rather than the 
total levels of Aβ species (Jarrett et al., 1993).  This reflects the higher hydrophobic  
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Fig. 2.  APP processing pathways.  (A) APP presents a large N-terminal ectodomain, which 
contains a portion of Aβ (red), while the remaining portion of the peptide is contained within the 
transmembrane region.  The cleavage sites for α- and β-secretases, as well as the the two most 
common cleavage sites for γ-secretase, are shown in the peptide sequence.  (B) Non-
amyloidogenic processing of APP by α- and γ-secretases, resulting in the production of sAPP α, 
CTF-α and ultimately CTF- γ and p3.  (C) Amyloidogenic processing of APP by β- and γ-
secretases, which generates sAPP-β and a membrane tethered CTF-β that is further cleaved by 
γ-secretase, yielding Aβ and CTF- γ.  Adapted from O’Brien and Wong, 2011. 
 
nature of Aβ42, more prone to aggregation.  In fact, Aβ42 is the main Aβ species 
detected at the core of amyloid plaques, and potentially the first form to aggregate, 
then triggering the misfolding of other Aβ species (Iwatsubo et al., 1994; Selkoe, 2001). 
The prominent role of Aβ in AD pathological events culminates in the 
construction of the amyloid cascade hypothesis. This hypothesis advocates that 
augmented Aβ generation and/or impaired Aβ clearance contributes to increased 
amounts of Aβ in the brain parenchyma, which then aggregate into higher assembly 
states that constitute the main pathological agent involved in AD progression, ultimately 
leading to neurodegeneration and dementia (Selkoe, 2001).  The amyloid cascade  
hypothesis is strongly supported by the finding of familial AD-related mutations in the 
genes coding for APP and for the catalytic subunits of γ-secretase, PS1 and PS2, 
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which are respectively associated with increased amyloidogenic processing of APP 
and preferential production of longer Aβ species with higher amyloidogenic propensity, 
such as Aβ42 (Selkoe, 2001; Reitz and Mayeux, 2014). 
In sporadic forms of AD, increasing evidence implicates impaired Aβ clearance 
as the initial event leading to Aβ accumulation.  For example, ApoE ε4 isoform is 
associated with defective Aβ clearance (Bu, 2009).  Furthermore, the activities of major 
Aβ-degrading enzymes, including neprilysin and insulin-degrading enzyme, have also 
been reported to be diminished with age and in AD brains (Wang et al., 2006). 
Since Aβ plaques are a major hallmark of AD, focus was initially given to the 
toxic properties of fibrillar Aβ (fAβ), the main constituent of SPs.  Curiously, despite 
some early studies reporting neurotoxic effects following fAβ exposure (Lorenzo and 
Yankner, 1994; Geula et al., 1998), it is now established that the presence of amyloid 
plaques do not directly correlate with cognitive decline in AD patients, while healthy 
aged individuals sometimes present high plaque number with no AD symptomology 
(Naslund et al., 2000; Cavallucci et al., 2012).  However, amyloid plaques can be the 
cause of indirect toxicity, since the presence of SPs is a key event in glial activation 
that drives neuroinflammation, other typical feature involved in AD progression (Meraz-
Rios et al., 2013). 
These results propelled further investigation, which ultimately revealed that 
higher levels of soluble Aβ oligomers (Aβo) show a robust correlation with extensive 
synaptic loss, as well as with cognitive deficits (Walsh and Selkoe, 2007; Cavallucci et 
al., 2012).  Further studies have identified several structurally diverse Aβo, usually 
formed from 9 to 50 molecules of the peptide that induce toxicity and neuronal 
dysfunction when administrated to neuronal cultures and mouse brains (Cavallucci et 
al., 2012; Kayed and Lasagna-Reeves, 2013). 
Regarding direct synaptic loss, growing evidence suggests that soluble forms of 
Aβo might physically interact with postsynaptic receptors, such as the N-methyl-D-
aspartate (NMDA) receptor, which limits Ca2+ influx through these receptors and 
triggers signalling cascades usually activated in long-term depression (LTD), a form of 
synaptic plasticity that reduces synaptic surface area and transmission (Shankar et al., 
2007; Knobloch and Mansuy, 2008; Selkoe, 2008). Different species of extracellular 
Aβo have also been reported to bind to other cell surface receptors, such as the nerve 
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growth factor and insulin receptors, which can possibly induce aberrant cellular 
responses and ultimately neurotoxicity (Yaar et al., 1997; Zhao et al., 2008; Kayed and 
Lasagna-Reeves, 2013).   
In addition to extracellular Aβ, there is evidence that Aβ in different assembly 
states can accumulate in several subcellular compartments, which further amplifies the 
plethora of pathological mechanisms attributed to Aβ (Kayed and Lasagna-Reeves, 
2013). Multiple studies indicate that Aβo interact with biological membranes and induce 
their permeabilization and/or formation of ionic pores, which is connected to leakage of 
lysosomal content into the cytosol and disruption of Ca2+ homeostasis (Yang et al., 
1998; Demuro et al., 2005; Kayed and Lasagna-Reeves, 2013). Aβ also induces 
endoplasmic reticulum (ER) stress, which further disrupts Ca2+ metabolism (Costa et 
al., 2010).  Altered levels of intracellular Ca2+ then contribute to mitochondrial 
dysfunction, reactive oxygen species (ROS) production, deregulation of signalling 
pathways and synaptic dysfunction, ultimately leading to neurodegeneration (Yu et al., 
2009). 
Taking into account the central function of mitochondria in the cell, there is no 
doubt that mitochondrial dysfunction, abnormal mitochondrial dynamics and 
degradation by mitophagy occurring during aging play a key role in AD progression 
(Kayed and Lasagna-Reeves, 2013).  Importantly, Aβ has been demonstrated to 
accumulate in brain mitochondria of both AD patients and mouse models, being 
detected before extensive amyloid deposition (Caspersen et al., 2005; Manczak et al., 
2006; Dragicevic et al., 2010).  Mitochondrial Aβ accumulation induced diminished 
enzymatic activity of respiratory chain complexes (III and IV) and subsequent decline in 
ATP production, while enhancing ROS production (Caspersen et al., 2005).  Moreover, 
since synaptic function has a high energy demand, mitochondrial failure may have a 
major role in synaptic failure in AD.  In fact, impaired synaptic plasticity in dentate 
granule cells is the earliest synaptic deficit in an AD mouse model, appearing to derive 
from mitochondrial dysfunction involving impaired Ca2+ uptake and increased ROS 
generation (Lee et al., 2012).   
Finally, Aβ can impair glutamate reuptake by glial cells, which leads to 
excitotoxic mechanisms that injure nearby neurons and increase ROS production 
(Esposito et al., 2013). As previously indicated, ROS production is a common feature of 
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several deregulated pathways involved in AD, while levels of reactive nitrogen species 
(RNS) derived from reactive glial cells, are also elevated (Meraz-Rios et al., 2013). 
Mounting evidence demonstrates extensive oxidative damage, including lipid 
peroxidation and protein and nucleic acid oxidation, in vulnerable brain regions of AD 
patients (Bonda et al., 2010).  Importantly, oxidative stress not only contributes to 
neuronal injury, as it may also potentiate Aβ production and aggregation.  In this 
regard, increased ROS levels leads to increased translation of BACE1 mRNA in the 
brains of AD patients and mouse models, thus enhancing the amyloidogenic 
processing of APP (Mouton-Liger et al., 2012).  The development of such self-
propelling cycles among Aβ-mediated aberrant mechanisms further hinders the 
isolation of the main pathological events involved in the etiology of AD. 
Altogether, the aforementioned Aβ-driven pathologic mechanisms contribute to 
deregulation of numerous signalling pathways in the brain, thus unbalancing activities 
of kinases and phosphatases. The deregulation of multiple signalling pathways then 
culminates in neuronal dysfunction and, ultimately, in neuronal cell death (Fig. 3).  
 
Fig. 3.  Proposed neurotoxic mechanisms for aggregated Aβ species.  At 
supraphysiological concentrations, Aβ can self-aggregate into higher order structures, ranging 
from low-n oligomers to insoluble fibrillar structures.  Mounting evidence suggest that soluble 
oligomeric species of Aβ are the main toxic forms of the peptide, appearing to be involved in 
numerous neurotoxic mechanisms that culminate in neuronal dysfunction and death.  Amyloid 
plaques, although appearing to lack direct neurotoxic effects beyond physically obstructing 
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neurites, are still important contributors to AD by eliciting a strong glial response leading to 
chronic neuroinflammation.  Adapted from Kotler et al., 2014. 
 
Regarding neurodegeneration, studies in the brain of AD patients showed a 
strong upregulation of apoptosis when compared to healthy age-matched controls, with 
activation of caspase-3 being detected in more than 50% of hippocampal neurons 
showing degenerated processes and co-localization with NFTs (Su et al., 2001; 
Colurso et al., 2003).  Further, plentiful in vitro studies have demonstrated the apoptotic 
properties of Aβ species (Sola et al., 2003; Shi et al., 2010; Kong et al., 2013).  These 
observations implicate apoptosis as a major form of Aβ-induced neuronal death. 
 
1.2.2. Neurofibrillary tangles 
In addition to Aβ plaques, neurofibrillary tangles are other typical 
histopathological feature of AD majorly constituted by hyperphosphorylated tau protein.  
Tau belongs to the family of microtubule-associated proteins (MAP), which are highly 
expressed in the CNS (Duan et al., 2012).  Tau is mainly allocated to axons, where it 
binds to the microtubules to promote their assembly and stability.  Further, binding of 
tau to the microtubules also regulates vesicular transport and axonal polarity.  In the 
adult brain, tau is expressed as six different isoforms, ranging between 352 and 441 
amino acid residues that derive from alternative splicing (Ballatore et al., 2007; Duan et 
al., 2012).  When unphosphorylated, tau is very hydrophilic, presenting a natively 
unfolded structure in solution.  The regulation of tau thus depends on conformational 
changes induced by residue-specific phosphorylations, with phosphorylation of more 
than 30 serine/threonine residues already described as modulating tau function 
(Stoothoff and Johnson, 2005).  Importantly, tau promotes microtubule assembly when 
presenting a reduced phosphorylation state.  The phosphorylation of tau in multiple 
residues has been attributed to several kinases, including glycogen synthase kinase 3β 
(GSK3β) and cyclin-dependent kinase 5 (CDK5).  Conversely, to counterbalance 
kinase activity, numerous phosphatases can dephosphorylate tau residues, including 
protein phosphatase 1 (PP1), 2A (PP2A), 2B (PP2B) and 2C (PP2C) (Duan et al., 
2012). Importantly, several tau-modifying kinases, such as GSK3β and CDK5, and 
phosphatases, such as PP2A, are consistently described as being deregulated in AD, 
thus leading to abnormal tau phosphorylation levels and subsequent tau malfunction 
12 
 
(Ballatore et al., 2007; Duan et al., 2012).  In particular, phosphorylation of Ser205, 
Ser396, Ser404, Thr205 and Thr212 enhance tau polymerization into filaments and 
NFTs (Necula and Kuret, 2005; Li and Paudel, 2006; Duan et al., 2012).  The direct 
role of tau aggregation in neurodegenerative processes are still not entirely 
understood, but it is known that tau dissociation destabilizes the axonal microtubule 
network, while toxic gain-of-function further drives tau aggregation.  These processes 
ultimately result in impaired axonal transport and lead to synaptic failure and 
neurodegeneration (Fig. 4) (Ballatore et al., 2007).   
 
Fig. 4.  Neurotoxicity mediated by tau dysfunction.  During normal conditions, tau stabilizes 
microtubules through direct binding.  This process is regulated by different tau phosphorylation 
patterns, which is tightly regulated by a large number of kinases and phosphatases.  However, 
during AD, the activities of these enzymes are severely unbalanced, leading to tau 
hyperphosphorylation and dissociation from the microtubules.  Hyperphosphorylated tau then 
aggregates into more organized forms until the formation of neurofibrillary tangles.  Reduced 
functional tau function and physical obstruction by insoluble NFTs then lead to impaired axonal 
transport and subsequently to neuronal dysfunction and death.  Adapted from Duan et al., 2012. 
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Supporting a prominent role for tau malfunction in dementia, mutations in the 
tau (MAPT) gene lead to the development of neurodegenerative disorders, termed 
tauopathies, such as the frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17) (Ballatore et al., 2007).  Moreover, unlike the distribution of 
amyloid plaques, the presence of tau pathology in AD is significantly correlated with 
neurodegeneration and the onset of clinical symptoms (Braak and Braak, 1991). 
Amyloid plaques and NFTs are predominant pathologic features of AD that 
develop in the same brain regions, but the interacting mechanisms between these 
players are still unclear. Multiple lines of evidence suggest that Aβ acts upstream of tau 
pathology, since AD patients and mouse models develop deregulated activities of 
kinases and phosphatases involved in regulation of tau function before the appearance 
of tau pathology  (Duan et al., 2012; Durairajan et al., 2012).  Curiously, decreased 
endogenous tau levels prevent cognitive deficits in APP overexpressing mice, without 
altering amyloid pathology.  In addition, APP/tau double transgenic mice present 
exacerbated tau pathology in areas with high levels of amyloid deposition when 
compared to single mutant tau transgenic mice, while amyloid deposition is not 
aggravated in the APP/tau mice as compared with single APP transgenic mice 
(Roberson et al., 2007; Duan et al., 2012).  In vitro studies have also detected tau 
hyperphosphorylation in mature hippocampal neurons treated with Aβ, further 
supporting the view that NFT pathology is a downstream effect of Aβ accumulation 
(Ferreira et al., 1997; Duan et al., 2012).  
 
2. Neuroinflammation in AD 
Chronic neuroinflammation is also a characteristic feature of AD (Selkoe, 2001; 
Hickman et al., 2008; Lyman et al., 2013).  It is well established that Aβ aggregates can 
elicit the development of inflammatory processes and increased gliosis, culminating in 
the abundant presence of activated microglia and reactive astrocytes in the close 
vicinity of amyloid plaques (Perlmutter et al., 1990; Hickman et al., 2008).  During AD 
progression, Aβ continues to accumulate, leading to prolonged pro-inflammatory 
signalling to glial cells. Upon activation, glial cells secrete pro-inflammatory molecules, 
including cytokines, chemokines, free radicals, prostaglandins and complement factors, 
which in turn induce their own expression, in a positive feedback loop (Meraz-Rios et 
14 
 
al., 2013).  This mechanism further exacerbates inflammation, which favors the 
amyloidogenic processing of APP, accumulation of Aβ and increased tau 
hyperphosphorylation, ultimately contributing to neurodegeneration. Increased Aβ 
levels potentiate the inflammatory response as well, leading to the generation of self-
propelling cycles (Mandrekar-Colucci and Landreth, 2010; Meraz-Rios et al., 2013). 
 
2.1. Microglia 
Microglia are the resident macrophages of the brain and spinal cord, 
constituting the main line of the innate immune defense in the central nervous system 
(CNS).  In humans, microglia comprise up to 16% of the CNS cellular population, while 
in rodents account for 5-12%, depending on brain region (Norden and Godbout, 2013).  
Microglial cells play a central role in neuroinflammation, being the major producers of 
pro-inflammatory mediators when activated. In the resting state, these cells present 
ramified extensions that constantly survey the surrounding microenvironment (Norden 
and Godbout, 2013).  Microglia possess several families of pattern recognition 
receptors that can, upon binding of recognizable evolutionary conserved motifs of 
microbial and viral-derived molecules classified as pathogen-associated molecular 
patterns (PAMPs), activate downstream signalling cascades that culminate in microglial 
activation.  Further, several of these receptors are also involved in the recognition of 
disparate molecules released from endogenous compartments or modified in structure, 
such as abnormal protein aggregates, that present damage-associated molecular 
patterns (DAMPs) (Landreth and Reed-Geaghan, 2009; Heneka et al., 2014). 
Upon activation, microglia change morphologically into an amoeboid shape and 
display increased expression of specific cellular surface receptors and key enzymes, 
presenting increased phagocytic capabilities and secretion of inflammation-related 
molecules.  Phenotypically, microglia can present M1 activation (or classical activation) 
or M2 activation (or alternative activation) (Lyman et al., 2013; Norden and Godbout, 
2013).  M1 activation is associated with an aggressive inflammatory response, leading 
to increased release of ROS and nitric oxide (NO), and production of pro-inflammatory 
mediators such as cytokines interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF-α), 
which are responsible for autocrine and paracrine inflammatory signalling in other glial 
cells and neurons.  There is also increased production of chemokines such as IL-8 and 
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monocyte chemoattractant protein 1 (MCP1), which attract other microglia and 
peripheral macrophages to the injury site.  On the other hand, M2 activation is 
classically stimulated by IL-4 and IL-13, being characterized by the repression of pro-
inflammatory gene expression and increased production of neurotrophic factors and 
anti-inflammatory cytokines such as IL-10, transforming growth factor β (TGF-β), IL-4 
and IL-13.  This phenotype reduces inflammation, promotes phagocytic capacities and 
potentiates tissue repair (Mandrekar-Colucci and Landreth, 2010; Lyman et al., 2013; 
Meraz-Rios et al., 2013; Norden and Godbout, 2013). 
Activated microglia are intimately associated with SPs in the brains of AD 
patients (Perlmutter et al., 1990).  Activated microglia proliferate locally and contribute 
to the recruitment of more microglial cells through the expression of chemokines 
(Meraz-Rios et al., 2013).  In AD pathology, initial microglial activation is thought to be 
regulated by direct binding of fAβ to several pattern recognition receptors, such as 
scavenger receptors and toll-like receptors (TLRs), inducing microglial activation and/or 
phagocytosis of bound Aβ (Wilkinson and El Khoury, 2012).  These include the 
scavenger receptors cluster of differentiation (CD) 36, α6β1-integrin, CD47 and 
scavenger receptor A-1 (SRA) multicomponent complex and the receptor for advanced 
glycation end-products (RAGE), as well as TLR2 and TLR4 (Bamberger et al., 2003; 
Wilkinson and El Khoury, 2012).  Engagement of these receptors generate intracellular 
signalling cascades that culminate in the activation of transcription factors associated 
with the expression of pro-inflammatory genes, including nuclear factor κB (NF-κB), 
activator protein 1 (AP-1) and the signal transducer and activator of transcription 3 
(STAT3), and/or receptor-mediated phagocytosis (Wilkinson and El Khoury, 2012).  
Despite the generalized microglial activation around SPs, these cells are 
incapable of clearing these deposits by phagocytosis.  Although several studies have 
determined that microglia can phagocyte Aβ in vitro, analysis of brain tissue from AD 
patients demonstrated that aggregated Aβ is not present in the lysosomal 
compartments of SPs-associated microglia (Frackowiak et al., 1992).  Furthermore, 
there is evidence that microglia isolated from aged rodents are senescent, presenting 
reduced Aβ phagocytic capacity and increased pro-inflammatory responses (Norden 
and Godbout, 2013).  Similar results are obtained with microglia isolated from non-
demented and AD brains, with AD-derived microglia presenting wider range and levels 
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of pro-inflammatory signalling mediators (Lue et al., 2001).  A recent study developed 
in APP/PS1 mice compared the expression levels of several Aβ receptors and Aβ-
degrading enzymes in microglia isolated from old mice (Hickman et al., 2008).  They 
observed decreased expression of SRA, CD36 and RAGE, along with reduced 
expression of the Aβ-degrading enzymes insulysin, neprilysin and matrix 
metalloproteinase 9 in microglia in older transgenic mice when compared to wild-type 
littermates.  Importantly, this was not detected in younger APP/PS1 mice.  Older 
microglia also presented increased expression of TNF-α and IL-1β.  A similar study 
further characterized the phenotype of activated microglia of APP/PS1 mice at 
increasing ages, concluding that there is an age-dependent shift from M2 activation, a 
phagocytic state, to M1 activation, a classical cytotoxic phenotype (Jimenez et al., 
2008).  Interestingly, compelling data have been showing that basal neuroinflammatory 
conditions are also augmented in non-demented human aged brains, with microglia 
preferably adopting the M1 pro-inflammatory phenotype in the elderly (Norden and 
Godbout, 2013). 
The development of a pro-inflammatory environment that negatively regulates 
microglial Aβ phagocytic activity indicates that loss of microglia Aβ clearance capacities 
is not only due to aging, but also to the chronic inflammatory milieu observed in AD 
pathology (Mandrekar-Colucci and Landreth, 2010). 
These results strongly support the hypothesis that, during the early stages of 
AD, microglia may alleviate amyloid burden and provide support to injured neurons by 
adopting a M2 activation phenotype.  However, with disease progression they shift 
towards the M1 activation state, losing Aβ clearance functions and further contributing 
to chronic neuroinflammation/neurodegeneration, with the formation of self-propelling 
cycles that potentiate AD-related pathologies. 
 
2.2. Astrocytes 
Astrocytes are the most abundant cells in the CNS, playing an essential role in 
brain homeostasis (Li et al., 2011).  They are enrolled in innumerous functions, 
including regulation of neuronal metabolism, neurotransmitter synthesis and recycling, 
ion homeostasis and regulation of neural and synaptic transmission (Sofroniew and 
Vinters, 2010).  They are also significant participators in the inflammatory response in 
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the CNS (Meraz-Rios et al., 2013).  In AD, astrocytes are activated around SPs, 
leading to increased number, size and motility of astrocytes and ultimately resulting in 
the sequestration of SPs within an outer ring of reactive astrocytes (Li et al., 2011).  
When activated, astrocytes produce several pro-inflammatory cytokines and 
chemokines, along with NO and ROS production, contributing to neuronal damage (Hu 
et al., 1998; Johnstone et al., 1999; Li et al., 2011).  Reactive astrocytes present high 
expression of intermediate filament proteins, including glial fibrillary acidic protein 
(GFAP) and vimentin (Pekny and Pekna, 2004; Wood-Kaczmar et al., 2009).  
Astrocytic activation also contributes to impaired neuronal activity.  For example, 
reactive astrocytes reuptake the neurotransmitter glutamate inefficiently, which 
culminates in excitotoxicity to proximal neurons (Meraz-Rios et al., 2013).  Studies in 
vitro have determined that astrocytes can be activated by exposure to Aβ aggregates, 
with subsequent production of pro-inflammatory cytokines, such as IL-1β, TNF-α, and 
inducible nitric oxide synthase (iNOS) with concomitant NO generation (White et al., 
2005).  It has been demonstrated that astrocytes express several receptors known to 
bind Aβ species and mediate Aβ-downstream pro-inflammatory signalling, such as 
receptor for advanced glycation end-products (RAGE) and TLRs (Trudler et al., 2010; 
Askarova et al., 2011).  Importantly, a recent study has also reported Aβ-dependent 
astroglial activation in vivo, with injections of oligomeric Aβ1-42 in the rat cortex (Perez et 
al., 2010; Carrero et al., 2012).  These injections resulted in marked activation of NF-κB 
in astrocytes, with a significant up-regulation of TNF-α and IL-1β (Carrero et al., 2012).  
Although activated, astrocytes can phagocytose Aβ species upon binding to the 
receptors CD36 and CD47 in vitro.  The importance of this ability to the progression of 
AD in patients or animal models is still to be determined (Jones et al., 2013). 
Reactive astrocytes also express increased levels of S100B, a neurotrophic 
factor that induces APP expression in neurons, further contributing to Aβ generation (Li 
et al., 1998; Hamed et al., 2009).  Apparently, S100B up-regulation depends on IL-1β 
levels (Liu et al., 2005a) involving S100B in a self-propagation cycle between Aβ and 
cytokine production, resulting in chronic neuroinflammation (Li et al., 2011). 
Finally, it has been demonstrated that astrocytes stimulated with pro-
inflammatory molecules usually overexpressed in AD, such as TNF-α, show increased 
APP and BACE1 levels, resulting in increased Aβ production (Blasko et al., 2000; Zhao 
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et al., 2011). Incubation of astrocytes with Aβo and fAβ dramatically increased APP 
and BACE1 levels through transcriptional mechanisms (Zhao et al., 2011).  Therefore, 
although neurons are the main producers of Aβ, astrocytes outnumber neurons in a 
five-to-one ratio, implicating activated astrocytes not only in neuronal injury, but also as 
a source of Aβ during CNS inflammation. 
 
2.3. Cytokines 
Activated microglia and astrocytes secrete cytokines, which are soluble 
signalling proteins that influence the inflammatory response in several cell types.  
Characterization of the pro-inflammatory cytokine repertoire in AD patient brain tissue 
and cerebrospinal fluid revealed a generalized elevation of these molecules, namely IL-
1β, IL-6, TNF-α and TGF-β (Blum-Degen et al., 1995; Licastro et al., 2000; Jiang et al., 
2011; Meraz-Rios et al., 2013).  These cytokines are highly produced in microglia and, 
to a minor extent, in astrocytes activated by Aβ aggregates (Tehranian et al., 2001; 
Meraz-Rios et al., 2013).  Increased production of pro-inflammatory cytokines is also 
extensively described in AD mouse models (Sly et al., 2001; Tehranian et al., 2001; 
Patel et al., 2005).  As such, several of these factors have been studied in AD contexts 
to evaluate their effect in AD progression. 
 
2.3.1.  TNF-α 
TNF-α is a pro-inflammatory cytokine that can potentiate both microglial and 
astrocytic activation in several neuroinflammatory conditions, and especially in AD 
(Rossi et al., 2005; Rubio-Perez and Morillas-Ruiz, 2012).  This cytokine has a dual 
role on neuronal survival and death by apoptosis, since TNF-α-downstream signalling 
mediated by TNF-α receptors (TNFR) 1 and 2 can either induce apoptosis by activation 
of caspase-8, or provide survival by activating NF-κB, depending on cellular context 
(Hohmann et al., 1990; Li et al., 2011).  TNF-α can also inhibit neurogenesis, which 
might contribute to the cognitive decline observed in early stages of AD (Liu et al., 
2005b). In vitro, TNF-α can potentiate γ-secretase activity, contributing to Aβ 
generation (Liao et al., 2004).  Furthermore, TNF-α stimulated BACE1 expression, thus 
increasing amyloidogenic APP processing in cultured astrocytes overexpressing 
Swedish mutant APP (Yamamoto et al., 2007).  These results might be explained by 
19 
 
the fact that TNF-α can activate NF-κB, which is a known inducer of BACE1 expression 
(Ly et al., 2013).  TNF-α may also play an important role in regulating Aβ phagocytosis, 
since cultured microglia treated with this cytokine presented decreased expression of 
CD36 and SRA along with reduced Aβ uptake (Hickman et al., 2008).   
Studies performed in a mouse model of chronic neuroinflammation reported 
increased TNF-α levels along with loss of cognitive function.  Importantly, treatment 
with an analog of thalidomide that inhibits TNF-α synthesis, reduced hippocampus 
TNF-α levels to levels similar to control mice, while ameliorating cognitive deficits 
(Belarbi et al., 2012).  Moreover, this same inhibitor has been transcribed as being 
therapeutic in an AD mouse model, attenuating amyloid deposition, decreasing gliosis 
and rescuing behavioral deficits (Tweedie et al., 2012).  Other study administered an 
anti-TNF-α monoclonal antibody to APP/PS1 mice, which resulted in reduced Aβ 
accumulation and tau hyperphosphorylation (Shi et al., 2011).  APP23 transgenic mice 
with genetic ablation of TNFR-1 also present decreased Aβ generation and attenuated 
cognitive deficits (He et al., 2007).  However, ablation of both TNF-α receptors in 
3xTgAD mice exacerbated Aβ pathology, while isolated microglia from this mouse 
model manifested decreased Aβ phagocytic activity (Montgomery et al., 2011).  This 
indicates that TNF-α signalling may have both protective and detrimental roles in AD 
pathology, arguing against long-term pan-anti-TNF-α treatments in AD. 
 
2.3.2.  IL-1β 
The IL-1 cytokine super family is basally expressed in the healthy CNS and 
includes IL-1α, IL-1β and IL-1 receptor antagonist.  All CNS cells (neurons, microglia, 
astrocytes and oligodendrocytes) can synthesise IL-1β and express the respective 
signalling receptor (Fogal and Hewett, 2008).  In physiological conditions, IL-1β is 
involved in the regulation of synaptic plasticity, contributing to LTP in the hippocampus 
(Balschun et al., 2003).  However, higher levels of this cytokine, induced by either 
direct IL-1β injection or induction of an acute peripheral inflammatory response, 
impaired spatial memory in mice (Gibertini et al., 1995).  IL-1β is a pro-inflammatory 
cytokine that sensitizes microglial cells and potently activates astrocytes (Carrero et al., 
2012; Lyman et al., 2013).  Upon binding to its receptor, IL-1β induces the activation of 
several signalling pathways, leading to increased production of IL-6 and IL-8 (Ridley et 
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al., 1997; Jung et al., 2002).  IL-1β-dependent p38MAPK signalling promotes 
cyclooxygenase-2 expression, whose products further induce the expression of IL-6, 
thus generating a positive feedback loop (Lacroix and Rivest, 1998; Lyman et al., 
2013).  The p38MAPK is also a kinase known to phosphorylate tau in neurons, thus 
contributing to NFT formation (Li et al., 2003).  In astrocytes, IL-1β increases the 
production of ROS and NO, further contributing to neuronal damage (Hu et al., 1998; 
Akama and Van Eldik, 2000).  IL-1β can also contribute to Aβ production by increasing 
γ-secretase activity in a JNK-dependent manner (Liao et al., 2004). 
Despite all the evidence implicating IL-1β in AD pathology, PS1Δ9 transgenic 
mice overexpressing IL-1β in the hippocampus presented decreased amyloid plaque 
formation with associated robust neuroinflammatory response (Shaftel et al., 2007).  It 
was hypothesized that these effects might reflect an enhancement of microglial Aβ 
phagocytosis, further highlighting the importance of the subtle balance between several 
inflammatory factors in affecting microglial phenotypic activation.  Of note, this mouse 
model presents elevated IL-1β levels since before amyloid deposition and not 
afterward, which complicates the interpretation of the endogenous role of this cytokine 
during AD progression. 
 
2.3.3.  IL-6 
IL-6 is a potent pleiotropic cytokine capable of inducing a strong inflammatory 
response in glial cells.  In the CNS, it can be secreted by microglia and, to a minor 
extent, by astrocytes (Lyman et al., 2013).  IL-6 receptor is expressed not only in glial 
cells, but also in neurons.  Studies in hippocampal tissue determined that IL-6 
expression is essential for sustained up-regulation of TNF-α and IL-1β (Sparkman et 
al., 2006).  IL-6 can up-regulate APP expression, further exacerbating Aβ production 
and generating another positive feedback loop (Ringheim et al., 1998). In neurons, IL-6 
signalling can activate the CDK5/p35 complex, which contributes to tau 
hyperphosphorylation (Quintanilla et al., 2004; Kitazawa et al., 2005).  IL-6 inhibits 
neurogenesis and neural differentiation in adult hippocampus (Liu et al., 2005b).   
Overexpression of IL-6 in the brains of an AD mouse model attenuates Aβ 
production and deposition and induces glial activation with increased expression of 
phagocytic markers, suggesting an improved Aβ clearance capacity (Chakrabarty, 
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2010).  Much like the IL-1β overexpressing AD mouse model, these results suggest 
that IL-6 up-regulation might promote Aβ clearance at earlier stages of AD pathology. 
 
Overall, the chronic neuroinflammatory conditions detected in AD brains are 
clearly involved with neurotoxic mechanisms and the potentiation of Aβ and tau 
pathologies, which further drives inflammation (Fig. 5). 
 
Fig. 5.  Neuroinflammatory processes in Alzheimer’s disease.  Aggregated Aβ species act 
like DAMP-like molecules, being able to bind to several microglial receptors, including TLRs, 
RAGE, CD47 and SRA.  Activation of these receptors then induces phagocytosis of bound Aβ 
and/or activation of transcription factors involved in the inflammatory response, which 
culminates in microglial activation and subsequent production of pro-inflammatory molecules, 
including oxidative species (ROS, RNS) and inflammatory cytokines (IL-1β, IL-6, TNF-α).  
Additionally, astrocytes are also important players in the inflammatory response by amplifying 
pro-inflammatory signalling, after becoming activated when exposed to Aβ and/or inflammatory 
molecules.  In turn, a strong inflammatory environment contributes to deregulation of several 
neuronal mechanisms, leading to increased Aβ production, tau hyperphosphorylation and, 
ultimately, to neuronal dysfunction and death.  Finally, elevated Aβ production further 
potentiates the inflammatory response, leading to the formation of a vicious cycle between both 
pathologies.  Adapted from Meraz-Rios et al., 2013. 
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3. AD diagnosis and therapy 
Recent guidelines for diagnostic criteria have been advanced that expand AD 
diagnosis into: (1) pre-symptomatic phase; (2) symptomatic, pre-dementia phase 
(MCI); and (3) dementia phase, based on clinical, neurological and psychiatric 
examinations, along with the usage of biomarkers that include biological fluid analyses 
and neuroimaging measures (Jack et al., 2011). 
The blood and cerebrospinal fluid (CSF) provide numerous biomarkers for AD, 
but CSF biomarkers present higher consistency among studies.  Promising CSF 
biomarkers include Aβ species and phosphorylated tau/total tau. Nevertheless, the 
levels of these proteins might vary in CSF depending on AD progression, which 
precludes a straightforward interpretation of the results (Reitz and Mayeux, 2014). 
Bioimaging techniques have also been employed in AD diagnosis, including magnetic 
resonance imaging (MRI), computed tomography (CT) and positron emission 
tomography (PET).  Structural MRI and CT scans can detect cerebral atrophy, which 
can be related to AD depending on the affected regions (Reitz and Mayeux, 2014).  
Further, PET scanning has been applied for the detection of amyloid aggregates and 
NFTs, after the introduction of radiotracers into the blood stream that can reach the 
brain and bind these AD structures (Shoghi-Jadid et al., 2002; Reitz and Mayeux, 
2014).  PET can also be used to study cerebral metabolism by using a radiolabelled 
form of glucose.  Importantly, cerebral metabolism is decreased in AD-affected brain 
regions (Landau et al., 2011).  Despite this complexity and extensive overlapping of 
clinical features with other dementias, it is already possible to diagnose AD with some 
certainty.  Nevertheless, definitive AD diagnosis can only be obtained post-mortem by 
microscopic examination of the cerebral cortex and subsequent identification of SPs 
and NFTs (Selkoe, 2001; Reitz and Mayeux, 2014).  Unfortunately, available 
treatments for AD are only focused on the management of symptoms, without affecting 
disease progression.  These include acetylcholinesterase inhibitors (donepezil, 
galanthamine, rivastigmine), which attempt to counteract impaired cholinergic function, 
and memantine, an antagonist of the NMDA subtype of glutamate receptors that 
prevent their overstimulation (Selkoe, 2001; Stone et al., 2011).  Therefore, multiple 
studies have proposed novel therapeutic strategies targeting several of the pathways 
deregulated in AD. 
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Several of these strategies are focused on decreasing Aβ 
production/aggregation or enhancing the clearance of Aβ and aggregated tau.  In this 
regard, posiphen, an inhibitor of β-secretase that precludes Aβ generation through the 
amyloidogenic pathway, is presently in clinical trials, with promising preliminary results 
(Maccecchini et al., 2012).  Further, compounds described to decrease Aβ aggregation 
in AD mouse models, such as scyllo-inositol and melatonin, are also in clinical trials 
(Stone et al., 2011).  Finally, Aβ-directed immunotherapy has been shown to reduce 
AD pathology in AD mouse models (Schenk et al., 1999; Lemere, 2013).  However, 
active anti-Aβ immunization induces severe auto-immune reactions in AD patients, 
including meningoencephalitis, while passive immunotherapy with antibodies directed 
to Aβ, despite promising, have yielded no significant clinical benefits (Lemere, 2013). 
Other options encompass antioxidant therapy with natural occurring 
antioxidants, such as vitamin E, C and B that appear to decrease AD risk, according to 
several longitudinal studies (Sano et al., 1997; Zandi et al., 2004; Stone et al., 2011).  
Interestingly, several synthetic antioxidants have been investigated in AD contexts, and 
the most promising results derive from compounds that target mitochondrial ROS 
production in AD in vitro and in vivo models (Siedlak et al., 2009; Stone et al., 2011). 
Several epidemiologic studies have determined that subjects treated for long 
periods with nonsteroidal anti-inflammatory drugs (NSAIDs) present a significantly 
lower risk for incidence of AD (Broe et al., 2000; Cote et al., 2012). However, following 
studies show no clinical effect in patients diagnosed with mild-to-moderate AD (Reines 
et al., 2004; Stone et al., 2011). Controversial results were also described for 
prevention trials for several NSAIDs, including naproxen and celecoxib (Martin et al., 
2008). 
In conclusion, AD is a complex neurodegenerative disorder that depends on 
numerous interlocked mechanisms for the onset of its pathological features.  
Furthermore, AD mechanisms may also be generated and/or potentiated by 
deregulated processes observed in normal aging, thus increasing the number of 
players involved in this multifactorial pathology.  Therefore, effective therapeutic 
intervention in AD will probably require multiple therapeutic agents directed toward 
several cellular and molecular deregulated targets implicated in AD. 
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4. Modeling AD in vivo 
The need for AD animal models that mimic AD progression led to the 
establishment of a plethora of transgenic AD mouse models that carry diversified 
combinations of familial AD mutations in APP and/or PS1/PS2 genes expressed from 
several promoters, which ultimately present Aβ deposition into SPs (Elder et al., 2010; 
Wirths and Bayer, 2010).  Nevertheless, other AD-associated phenotypes are 
differentially observed among the available transgenic models, with none of them fully 
recapitulating the cognitive decline described in AD patients (Bryan et al., 2009; 
Webster et al., 2014).  In fact, overexpression of APP and/or PS1 using artificial 
promoters poses several drawbacks, such as overproduction of APP and its cleavage 
fragments besides Aβ, which can also impact on AD-associated phenotypes (Born et 
al., 2014; Saito et al., 2014).  Further, AD transgenic mice do not develop neurofibrillary 
tangle pathology, the second hallmark of AD, despite presenting tau 
hyperphosphorylation (Ribe et al., 2005).  In this regard, mice carrying APP and PS1 
transgenes, along with overexpression of mutant human tau, have been developed in 
order to recapitulate the features of tau pathology observed in AD patients, with some 
success (Wirths and Bayer, 2010; Ribe et al., 2005). 
Nevertheless, double-transgenic mice carrying mutations associated with EOAD 
in APP and PS1 genes are among the most successful models, developing Aβ plaques 
and a robust neuroinflammatory response towards these aggregates, along with loss of 
synaptic integrity and associated memory and cognitive impairments (Radde et al., 
2006; Elder et al., 2010; Balducci and Forloni, 2011).  However, most APP 
overexpressing transgenic mouse models of AD present limited and usually localized 
neuronal death several months after most AD-related features are already present, 
even in the presence of massive amyloid load  (Elder et al., 2010; Wirths and Bayer, 
2010; Rupp et al., 2011).  These features contrast with AD patients in advanced stage 
of the disease, in which neuronal death can reach approximately 90% for layer II of the 
entorhinal cortex (Gomez-Isla et al., 1996).  Several explanations for this general 
difference between AD patients and mouse models have been advanced.  For 
example, neurons in the mouse brain can be more resistant to neurotoxic effects 
exerted by Aβ species derived from human APP overexpression, by presenting 
different coping mechanisms or different levels of neuronal Aβ targets; however, 
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cultured primary mouse neurons can still undergo massive apoptosis when exposed to 
Aβ (Watson and Fan, 2005).  Further, overexpression of APP itself may be 
neurotrophic, since it has been demonstrated that several transgenic mice strains that 
overexpress APP with different mutations present higher cortical neuron size and 
number at early stages of disease, when compared to wild-type mice (Bondolfi et al., 
2002; Oh et al., 2009).  Moreover, Aβ produced from the overexpression of APP in 
mice brain lack most of the complex post-translational modifications, truncated forms 
and cross-linked features observed in the brains of AD patients, which might explain 
different neurotoxic effects (Kalback et al., 2002).  Also, virtually no APP 
overexpressing mice develop NFTs, unless elevated tau levels are obtained artificially 
through transgenic approaches (Rupp et al., 2011).  Interestingly, intraneuronal Aβ 
levels have been implicated in extensive neuronal loss in some APP/PS1 mouse 
models (Casas et al., 2004; Oakley et al., 2006).  
Nevertheless, AD animal models remain instrumental for the elucidation of 
molecular pathways involved in AD and for the development of possible therapies to 
treat this devastating neurodegenerative disease. 
 
5. Targeting the PI3K/Akt/GSK3 signalling pathway 
The phosphatidylinositide 3-’OH kinase (PI3K)/Akt signalling pathway is 
implicated in the modulation of multiple cellular pathways involved in metabolism 
regulation and energy homeostasis (Peltier et al., 2007; O’Neill, 2013).  There are 
many growth factors capable of activating PI3K, such as insulin and insulin-like growth 
factor 1 (IGF1).  When activated, PI3K produces phosphatidylinositol-3,4,5-
trisphosphate (PIP3), which in turn recruits the serine-threonine kinase Akt to the 
membrane. Here, Akt is phosphorylated at Thr308 by phosphoinositide-dependent 
protein kinase-1 (PDK-1), which allows for mTORC2-mediated phosphorylation of Akt 
at Ser473, fully activating this kinase (Fig. 6) (Beaulieu et al., 2009; O'Neill, 2013). 
In the brain, the PI3K/Akt pathway is involved in the regulation of mechanisms 
of neuronal plasticity.  During brain development, PI3K/Akt modulate proliferation, cell 
migration, axon guidance and establishment of neuronal polarity (Peltier et al., 2007; 
Akiyama and Kamiguchi, 2010).  Further, PI3K/Akt downstream signalling induces the  
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Fig. 6.  Regulation of PI3K/Akt signalling.  Binding of insulin, IGF1 or other growth factors 
activates their tyrosine kinase receptors by autophosphorylation, which then recruit IRS-1/2, 
thereby activating PI3K.  PI3K produces PIP3, which recruits Akt to the membrane, allowing for 
the interaction with PDK1 and subsequent phosphorylation of Akt at Thr308.  This allows for 
mTORC2-mediated phosphorylation of Akt at Ser473, which fully activates this kinase.  Akt can 
then phosphorylate a broad range of substrates involved in cellular function, including GSK3.  
Termination of PI3K/Akt signal transduction depends on dephosphorylation of PIP3 by 
phosphatase and tensin homolog (PTEN), dephosphorylation of Akt by PP2A and PH domain 
leucine-rich repeat protein phosphatases (PHLPPs), and negative feedback inhibition via 
mTOR/mTORC1.  Adapted from O’Neill, 2013. 
 
activation of the cAMP response element-binding (CREB) transcription factor, which in 
turn promotes proliferation of hippocampal neuronal cells (Peltier et al, 2007).  In the 
adult brain, PI3K/Akt signalling increases the survival rate of new hippocampal granule 
cells in the dentate gyrus, thus increasing synaptic plasticity (Bruel-Jungerman et al., 
2009). 
In fact, activation of PI3K/Akt signalling is crucial for hippocampal expression of 
late-phase long-term potentiation (LTP), a form of synaptic plasticity closely related 
with learning and memory (Horwood et al., 2006; Karpova et al., 2006).  Interestingly, 
insulin receptors appear to be directly implicated in learning and memory by 
upregulating synaptic function in the hippocampus, which depends on PI3K/Akt 
activation (Zhao et al., 1999).  Akt expression is also necessary for neuronal survival 
during normal and stress-inducing conditions, especially in those involving oxidative 
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stress (Crowder and Freeman, 1998; Kang et al., 2003; Murata et al., 2011). Finally, 
the PI3K/Akt/mammalian target of rapamycin kinase (mTOR) pathways increases both 
presynaptic and postsynaptic protein synthesis, an important mechanism for the 
maintenance of enhanced synaptic strength (Je et al., 2011). 
Importantly, Akt can phosphorylate GSK3α/β at serine 21/9, which strongly 
inhibits the activity of this multifaceted enzyme (Beaulieu et al., 2009).  GSK3 is a 
partially constitutively active serine/threonine kinase ubiquitously expressed in all 
mammals.  GSK3 is generated from two distinct genes as two highly homologous 
isoforms, GSK3α and GSK3β (Woodgett, 1991; Soutar et al., 2010).  Although both 
isoforms exert similar functions, they are differentially expressed among cell types, 
being GSK3β preferentially expressed in the nervous tissue (Soutar et al., 2010).  
Initially identified by its ability to phosphorylate glycogen synthase, GSK3 is now known 
to be a multifunctional enzyme targeted by many signalling pathways, being able to 
phosphorylate more than 50 substrates (Jope and Johnson, 2004; Sutherland, 2011).  
Several of these targets are transcription factors, further highlighting the fundamental 
role of GSK3 in the regulation of cellular responses (Jope and Johnson, 2004).  Due to 
its multiple targets, GSK3 activity is tightly regulated.  One main upstream regulatory 
mechanism is inhibition of GSK3 by direct phosphorylation of Ser21 in GSKα, and Ser9 
in GSK3β (Sutherland et al., 1993; Jope and Johnson, 2004).  Several kinases can 
phosphorylate this residue, including protein kinase A (Votypka et al.), protein kinase B 
(PKB)/Akt and protein kinase C (PKC) (Jope and Johnson, 2004).  On the other hand, 
optimal GSK3 activity is achieved by phosphorylation of Tyr279 in GSKα, and Tyr216 in 
GSK3β (Lochhead et al., 2006).  Other regulatory mechanisms are mostly engaged in 
the fine-tuning of GSK3 selectivity for specific substrates.  Downstream mechanisms 
include pre-phosphorylation (priming) of the substrates at 4-5 residues from GSK3 
phosphorylation site.  Most substrates must be primed to be phosphorylated by GSK3, 
which implicate coordinated activity between the priming kinase and GSK3 (Dajani et 
al., 2001).  GSK3 is also contained in multi-protein complexes that regulate substrate 
accessibility, as exemplified by the substrate β-catenin in the Wnt pathway (Frame and 
Cohen, 2001).  GSK3 is also translocated to the nucleus and mitochondria, and 
regulation of its subcellular location or its inhibitory-phosphorylation state in these 
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cellular compartments further restricts substrate accessibility (Jope and Johnson, 
2004). 
 
5.1. PI3K/Akt/GSK3 deregulation in AD 
The PI3K/Akt/GSK3 axis is consistently described as being deregulated in AD 
(Ryder et al., 2004; Lee et al., 2009; de la Monte, 2012; Durairajan et al., 2012). 
Similarly, brain insulin resistance is widely detected in the brains of AD patients and 
mouse models, leading to reduced responses of the insulin signalling pathway 
mediated by the insulin receptor (IR), insulin receptor substrate-1 and -2 (IRS1,2) and 
PI3K/Akt pathway (Liu et al., 2011; de la Monte, 2012; Talbot et al., 2012).  
Interestingly, Aβ-induced cellular stress has been correlated with activation of JNK, 
which can phosphorylate and abolish the activity of IRS-1,2 leading to impaired 
insulin/PI3K/Akt signalling (Bomfim et al., 2012; Jia et al; 2013). Ultimately, this impacts 
on synaptic plasticity, neuron metabolism, neurodegeneration and cognitive decline (de 
la Monte, 2012; Liu et al., 2011).  In vitro, Aβ-induced apoptosis is also readily inhibited 
by the activation of the PI3K/Akt pathway (Sola et al., 2003; Shi et al., 2010; Kong et 
al., 2013).   
Conversely, several reports have detected abnormal upregulation of PI3K/Akt 
signalling pathway in AD brains, which can be involved in the development of insulin 
resistance through feedback mechanisms (Talbot et al., 2012). Oral administration of 
the PI3K inhibitor wortmannin resulted in reduced Aβ deposition in the Tg2576 
transgenic mouse model of AD (Haugabook et al., 2001), and PI3K inhibition in 
neuroblastoma cells overexpressing APP resulted in decreased Aβ production and 
secretion, along with APP accumulation inside the cells, probably due to limited 
vesicular trafficking (Petanceska and Gandy, 1999).  Increased mTOR activity, a 
downstream target of PI3K/Akt, also appears to be associated with AD progression.  In 
this regard, mTOR can upregulate both tau and APP (Westmark and Malter, 2007; 
Morita and Sobue, 2009).  Further, mTOR negatively modulates autophagy and the 
clearance of protein aggregates, which possibly contributes to neurodegeneration 
(Heras-Sandoval et al., 2014). 
Therefore, the contribution of the PI3K/Akt pathway to AD is still a matter of 
intense debate and is far from clear.  One possible explanation is that the PI3K family 
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comprises different PI3K isoforms that are differentially expressed among the CNS 
(Rodgers and Theibert, 2002).  The differential expression of these various isoforms, 
allied to their subcellular location and metabolic cellular context (Hawkins et al., 2006) 
can possibly justify the divergent opinions toward the role of PI3K/Akt signalling in AD.  
Further work is thus needed to elucidate the complex mechanisms linking insulin 
resistance, PI3K/Akt deregulation and AD progression. 
On the other hand, GSK3 hyperactivity has been extensively correlated with AD 
pathology.  The brains of AD patients present increased GSK3 activity in affected brain 
regions, a feature widely mimicked in vivo by AD mice, and in vitro by cell cultures 
harbouring familial AD mutations or exposed to Aβ (Ryder et al., 2004; Lee et al., 2009; 
Jimenez et al., 2011; Durairajan et al., 2012). 
In this regard, GSK3β is known to be the main kinase responsible for tau 
phosphorylation at multiple sites, and deregulation of this enzyme is consequently 
highly involved in tau hyperphosphorylation and subsequent formation of NFTs 
(Ishiguro et al., 1993; Takashima et al., 1998).  Moreover, GSK3β can also 
phosphorylate APP, which increases APP endoproteolysis through the amyloidogenic 
pathway (Aplin et al., 1996; Lee et al., 2003).  GSK3-dependent phosphorylation of 
APP (p-APP) at the cytoplasmic residue Thr668 targets the protein for fast axonal 
transport to nerve terminals.  Axonal transport increases the co-localization of p-APP 
with β- and γ-secretases within axonal or presynaptic vesicles, which culminates in 
enhanced Aβ generation (Lee et al., 2003; Lee et al., 2005; Durairajan et al., 2012).  
Interestingly, specific GSK3β inhibition resulted in decreased BACE1 expression in an 
AD mouse model, with a concomitant decrease in the amyloidogenic processing of 
APP (Ly et al., 2013).  These results implicate GSK3 in both APP phosphorylation and 
elevated BACE1 expression, two processes involved in increased amyloidogenic 
processing of APP.  GSK3β overexpression also impairs learning and memory in mice 
(Zhu et al., 2007).  Moreover, GSK3 can activate intrinsic pro-apoptotic pathways in 
injured neurons (Fig. 7) (Mines et al., 2011).  Increased GSK3β activity is also 
associated with decreased β-catenin levels in neural progenitor cells, impairing 
neurogenesis (Kitazawa et al., 2011).  
Finally, inhibition of GSK3 in vivo has already been proven to ameliorate all 
major AD-associated pathologies (Sereno et al., 2009; Durairajan et al., 2012).  
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Overall, GSK3 is implicated in all major pathological mechanisms involved in AD, 
highlighting the modulation of GSK3 activity as a promising therapeutic target to treat 
AD. 
 
 
Fig. 7.  Proposed mechanisms linking neuronal GSK3 deregulation and AD progression.  
In neurons, deregulated GSK3 activated is highly involved in tau hyperphosphorylation and 
subsequent formation of NFTs, a pathological hallmark of AD.  GSK3-dependent 
phosphorylation of APP is also believed to increase Aβ production.  Interestingly, GSK3 may 
also increase BACE1 expression, further elevating Aβ generation.  Moreover, GSK3 
hyperactivity is linked to disrupted neuronal function and induction of apoptotic pathways during 
stress conditions.  Adapted from Jope et al., 2004. 
 
5.1. GSK3 in neuroinflammation 
GSK3 is an important mediator of innate and adaptive immune responses 
(Beurel et al., 2010). Interestingly, GSK3 was recently identified as playing a key role in 
pathways involved in glial activation, which is relevant to AD (Koistinaho et al., 2011). 
Inhibition of GSK3 significantly decreases microglial migration in both in vitro cultures 
and hippocampal organotypic slices (Yuskaitis and Jope, 2009).  Furthermore, GSK3 
inhibition also results in decreased microglial inflammatory activation, reducing 
production of IL-6 and iNOS and protecting against inflammation-induced neurotoxicity 
(Yuskaitis and Jope, 2009). 
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GSK3 can regulate the expression of several inflammatory mediators, usually 
promoting the expression of pro-inflammatory molecules, while decreasing anti-
inflammatory factors (Martin et al., 2005; Beurel et al., 2010; Koistinaho et al., 2011).  It 
has been established that this effect depends on the regulatory role of GSK3 on the 
activation of multiple transcription factors and interaction with signalling pathways, 
including NF-κB, STAT3 and the JNK pathway (Steinbrecher et al., 2005; Wang et al., 
2010).  In microglia, GSK3-dependent activation of NF-κB results in increased 
expression of iNOS and pro-inflammatory cytokines and chemokines, such as TNFα, 
and IL-6 (Fig. 8) (Yuskaitis and Jope, 2009; Wang et al., 2010; Koistinaho et al., 2011). 
Further, inactivation of GSK3 increases inflammatory tolerance in astrocytes 
upon repeated inflammatory stimuli, indicating that inhibition of GSK3 might be 
beneficial during chronic neuroinflammatory conditions by decreasing sustained 
astroglial inflammatory response (Beurel and Jope, 2010). GSK3 has also been 
implicated in the activation of the transcription factor CCAAT/Enhancer-binding protein 
Delta (CEBPD) by direct phosphorylation, which appears to alter the pool of 
inflammatory molecules secreted by astrocytes (Ko et al., 2014). 
 
Fig. 8.  GSK3β upregulates pro-inflammatory pathways in microglia.  It has been 
demonstrated that GSK3β can directly activate transcription factors involved in the expression 
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of pro-inflammatory genes by phosphorylation, such as STAT3 and the p65 subunit of NF-κB.  
In the nucleus, p65 binds the co-activator of transcription CREB-binding protein (CBP) making it 
is less available to bind CREB, and upregulate expression of anti-inflammatory IL-10.  Further, 
GSK3 can also upregulate IL-6 expression by mixed lineage kinase 3 (MLK3)-dependent 
activation of JNK pathways.  Adapted from Koistinaho et al., 2011. 
 
6. Using bile acids as a therapeutic approach 
Bile acids are a class of acidic sterols that present a 
cyclopentanoperhydrophenanthrene nucleus (ABCD-ring) usually derived from a C24-
skeleton with a terminal carboxylic acid group, constituting the main type of molecules 
secreted in the bile.  Bile acids constitute the main type of molecules secreted in bile, 
being synthesized in the liver from neutral sterols through complex series of chemical 
reactions catalyzed by multiple enzymes that are involved in the cholesterol metabolic 
pathway (Russell and Setchell, 1992).  Interestingly, the intermediates and end-
products of bile acid pathways modulate the expression of genes involved in the 
synthesis of cholesterol, fatty acids and bile acids, mainly by interacting with DNA-
binding nuclear receptors (Repa and Mangelsdorf, 1999).  The primary bile acids 
derived from bile acid biosynthesis are usually conjugated with glycine or taurine, being 
then secreted via the bile ducts into the small intestine.  There, bile acids act mainly as 
detergents to emulsify dietary lipids, due to their amphipathic structure that allows them 
to be water-soluble and capable of inserting themselves into biological membranes.  
After uptake of emulsified nutrients, bile acids are re-absorbed to the liver via the portal 
vein, and are re-directed to the gallbladder for storage until the next feeding cycle 
(Russell and Setchell, 1992).  Interestingly, the primary bile acid pool that enters the 
small intestine can suffer biotransformation catalyzed by intestinal bacteria, yielding 
secondary and terciary bile acids, such as ursodeoxycholic acid (UDCA) (Hagey et al., 
1993). 
Modifications of bile acids lead to altered physicochemical properties, either 
increasing or decreasing their hydrophobicity.  Importantly, hydrophobic bile acids can 
act as cytotoxic molecules not only due to destabilization of biological membranes, but 
also as activators of extrinsic and intrinsic death pathways within the cell. On the other 
hand, hydrophilic bile acids such as UDCA are cytoprotective in several cellular 
contexts (Amaral et al., 2009). 
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UDCA is a hydrophilic bile acid increasingly used for the treatment of patients 
with hepatobiliary disorders, being widely considered as the first choice therapy for 
chronic cholestatic diseases (Roma et al., 2011).  Interestingly, the cytoprotective 
properties of UDCA derive from its ability to abrogate apoptosis, although the molecular 
mechanisms engaged in this response are still not entirely unraveled. It is known that it 
involves stabilization of mitochondrial membranes, decreased Bax translocation into 
the mitochondria and reduced opening of the permeability transition pore, which further 
restricts cytochrome c release and subsequent caspase activation and substrate 
cleavage (Rodrigues et al., 1998a; Rodrigues et al., 1998b; Rodrigues et al., 1999).  
Further, UDCA has been demonstrated to strongly modulate the expression of several 
genes involved in apoptosis, cell cycle regulation and proliferation in hepatocytes 
(Castro et al., 2005). 
 
Fig. 10.  Chemical structure of UDCA, here presented as the taurine conjugate form of 
UDCA.  Adapted from Berger and Haller, 2011. 
 
Tauroursodeoxycholic acid (TUDCA) is an endogenous hydrophilic bile acid that 
derives from the conjugation of UDCA with taurine (Fig. 10) (Amaral et al., 2009). 
Importantly, TUDCA presents strong anti-apoptotic properties in multiple cellular 
contexts, including several experimental models of neurodegeneration.  TUDCA is also 
a potent inhibitor of the ER stress-mediated pathways, reducing calcium efflux and 
activation of caspase-12 (Xie et al., 2002; Zhang et al., 2014).  Importantly, TUDCA 
inhibits multiple Aβ-induced apoptotic mechanisms.  A striking feature of TUDCA is its 
ability to act as a mitochondrial membrane stabilizer, abrogating membrane swelling, 
lipid peroxidation and cytochrome c release in neuronal cells and isolated rat 
mitochondria exposed to Aβ species (Rodrigues et al., 2000; Rodrigues et al., 2001).  
Further, TUDCA can also prevent Aβ-induced apoptosis by reducing JNK-dependent 
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activation of caspase-2, and interfering with p53-dependent pathways (Ramalho et al., 
2004; Ramalho et al., 2006; Viana et al., 2010). 
Curiously, bile acids are chemically similar to steroid hormones, thus allowing 
their interactions with nuclear steroid receptors (NSR) (Sola et al., 2006a).  In fact, 
TUDCA can physically interact with the NSR mineralocorticoid receptor (MR), thus 
counter-acting the reduced transactivation of this receptor after Aβ exposure and 
subsequently downregulating Aβ-dependent apoptosis (Sola et al., 2006b).  Moreover, 
TUDCA decreases Aβ and glutamate-induced mitochondrial dependent-apoptosis in 
primary rat cortical neurons by activating the pro-survival PI3K/Akt signalling cascade, 
which leads to Bad phosphorylation and subsequent reduction of Bad translocation into 
the mitochondria (Fig. 9) (Sola et al., 2003; Castro et al., 2004).  Interestingly, TUDCA 
has also been reported to inactivate GSK3β and reduce inflammation in liver tissue 
after partial hepatectomy, suggesting that TUDCA may target the Akt/GSK3 pathway in 
several cell types (Ben Mosbah et al., 2010). 
 
Fig. 9.  Anti-apoptotic mechanisms elicited by TUDCA.  TUDCA potently inhibits ER stress, 
thus precluding calcium leakage and subsequent caspase-12 activation.  TUDCA can also 
protect from Aβ-induced apoptosis by modulating multiple pathways.  In this regard, TUDCA 
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inhibits the apoptotic mitochondrial pathway by inhibiting Bax translocation, mitochondrial 
membrane permeabilization, cytochrome c release, and caspase-activation.  TUDCA can also 
interact with the mineralocorticoid receptor (MR), forming a functional complex that undergo 
nuclear translocation.  There, TUDCA downregulates p53 activity, probably through the 
transcription factor E2F-1, which further prevents apoptosis.  TUDCA can also prevent JNK-
dependent caspase-2 activation, while eliciting the activation of pro-survival pathways, such as 
PI3K/Akt.  Adapted from Amaral et al., 2009. 
 
Importantly, TUDCA enters the systemic circulation by oral administration and is 
able to cross the blood-brain barrier, greatly increasing the brain bioavailability of this 
bile acid (Keene et al., 2002).  In this respect, the neuroprotective effects of TUDCA 
have been demonstrated in several animal models of neurodegenerative diseases, 
including Alzheimer’s, Huntington’s (Keene et al., 2001; Keene et al., 2002) and 
Parkinson’s diseases (Duan et al., 2002; Castro-Caldas et al., 2012), and ischemic and 
hemorrhagic stroke (Rodrigues et al., 2002; Rodrigues et al., 2003).  Regarding AD, 
TUDCA presents therapeutic efficacy in APP/PS1 double-transgenic mice fed with a 
diet containing 0.4% TUDCA for 6 months (Nunes et al., 2012).  Notably, TUDCA 
treatment significantly decreased Aβ levels and deposition in mice brain as well as 
neuroinflammation, which was markedly correlated with amelioration of memory deficits 
(Lo et al., 2013; Nunes et al., 2012).  Further, TUDCA reduced the loss of the 
postsynaptic marker postsynaptic density-95 (PSD-95) and the decrease in 
spontaneous miniature excitatory postsynaptic currents (mEPSCs) frequency, while 
increasing dendritic spines density in primary rat cortical cultures exposed to Aβ.  More 
importantly, TUDCA treatment of APP/PS1 mice abrogated the reduction in PSD-95 
reactivity in the hippocampus (Ramalho et al., 2013). 
Finally, TUDCA appears to possess intrinsic anti-inflammatory properties.  In 
this regard, TUDCA has been shown to decrease glial activation and microglial 
migration in acute neuroinflammation models both in vivo and in vitro (Yanguas-Casas 
et al., 2014).  Other studies also showed the anti-inflammatory properties of bile acids 
similar to TUDCA, such as UDCA and glycoursodeoxycholic acid (GUDCA), in 
astrocytes and microglia exposed to pro-inflammatory stimuli, including Aβ (Joo et al., 
2003; Fernandes et al., 2007). 
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7. Objectives 
Given the promising results of TUDCA treatment before the onset of amyloid 
pathology in an AD transgenic mouse model, we hypothesized that administration of 
TUDCA after disease onset is beneficial and ameliorates Aβ pathology. TUDCA has 
already been demonstrated to activate the PI3K/Akt pathway, highlighting this pathway 
as a possible relevant target of TUDCA in an animal model that overproduces Aβ.  
Further, Akt negatively regulates GSK3, an enzyme widely characterized as 
hyperactivated in AD and involved in all its major aspects.  Finally, TUDCA presents 
anti-inflammatory properties  
 The main objectives of this study were: 
- To evaluate whether TUDCA modulates Aβ deposition and production; 
- To determine the effect of TUDCA on GSK3 activity levels and its 
downstream targets; 
- To characterize the protective role of TUDCA in AD-mediated 
neuroinflammatory response. 
 
Due to the lack of appropriate therapies to treat AD, TUDCA stands as a 
promising therapeutic strategy to treat this disease, possibly by acting on multiple 
therapeutic targets. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II. MATERIALS AND METHODS 
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Transgenic mice and treatment 
APP/PS1 double-transgenic mice, maintained on a C57BL/6J genetic 
background, coexpress KM670/671NL “Swedish” mutated human APP695 and L166P 
mutated human PS1 under the regulatory control of a murine Thy-1 minigene promoter, 
which is a neuron-specific promoter that restricts transgene expression to the postnatal 
period (Radde et al., 2006).  The Swedish double APP mutation leads to early-onset 
familial AD, mainly by increasing APP affinity for β-secretase, which results in elevated 
amyloidogenic processing of APP and subsequent higher Aβ production (Mullan et al., 
1992;Haas et al., 2012).  Since this mutation strongly enhances Aβ production, it is 
widely used for the generation of mouse models displaying Aβ pathology (Balducci and 
Forloni, 2011).  The Leucine to Proline mutation at position 166 of PS1 is one of the 
most aggressive familial AD mutation described so far, since its presence accelerates 
disease onset to as early as 24 years of age (Moehlmann, 2002; Bentahir et al., 2006).  
The PS1-L166P mutation induces the highest Aβ42 to Aβ40 ratio in transfected cells 
among several other PS1 mutations (Moehlmann et al., 2002). 
Mice were genotyped by PCR analysis of tail DNA.  All animals were housed in 
standard cages with ad libitum access to food and water in a temperature-controlled 
environment with a 12h light/dark cycle.  Male APP/PS1 mice and wild-type (wt) 
littermates were randomly assigned to four groups: TUDCA-treated and untreated 
(control) wt mice, and TUDCA-treated and untreated (control) APP/PS1 mice.  At 7 
months of age, animals were injected with either TUDCA (500 mg/kg of body weight) or 
vehicle every 3 days for 3 months (Fig. 1). 
The dosage of TUDCA used was calculated based on previous studies 
developed in rodents, including APP/PS1 mice (Keene et al., 2002; Nunes et al., 2012).  
Animals with 7 months of age were used to evaluate the protective effects of TUDCA 
after the onset of amyloid pathology, since amyloid deposition in APP/PS1 mice starts 
at 6 weeks of age in the neocortex while, in the hippocampus, deposition starts at 2-3 
months in the dentate gyrus and 3-4 months in the Cornu Ammonis 1 (CA1) (Radde et 
al., 2006). 
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Fig. 1.  Schematic timeline for TUDCA treatment in wt and APP/PS1 mice. 
Important time points are shown: at 2 months, APP/PS1 mice start presenting Aβ deposition in 
both neocortex and hippocampus; at 7 months of age, when amyloid pathology is firmly 
established, intraperitoneal (i.p.) injections containing TUDCA were administrated every 3 days 
for 3 months; at 10 months, all animal were tested for special memory and then sacrificed. 
 
Morris Water Maze 
Spatial learning was evaluated in the Morris water maze as previously 
described (Goddyn et al., 2006; Lo et al., 2013).  Briefly, mice were trained in a total of 
10 days (specifically in 2 series of 5 training days, with 2 days of rest between each 
series) to find a submerged platform.  Four trials starting from four different starting 
positions were performed each day with a trial interval of 30 min.  When mice failed to 
find the hidden platform within 2 min, they were guided to the platform and were left 
there for 15 s, before being returned to their cages.  Latency to find the hidden platform 
was recorded with Ethovision (Noldus Bv, Wageningen, The Netherlands).  To evaluate 
retention memory, probe trials were introduced on days 6 and 11. During these probe 
trials, the platform was removed and the swimming path was recorded during 100 s. 
Time spent in each quadrant was measured. 
 
Immunohistochemistry 
Saline-perfused brains were excised and one hemisphere was snap frozen for 
protein extraction.  The other hemisphere was fixed in 4% paraformaldehyde for 48 h 
and stored in 30% sucrose/phosphate buffered saline (PBS) at 4ºC.  The treated 
hemispheres were further dehydrated and embedded in paraffin. Sequential coronal 
brain sections (4-μm thick) were obtained and mounted on SuperFrost-Plus glass 
slides (Thermo Scientific, Rockford, IL, USA).  For immunostaining, brain sections were 
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deparaffined, rehydrated and antigen retrieval was performed by boiling the sections 
for 20 min in 10 mM citrate buffer, pH 6.   
The sections were then blocked for 1 h in Tris buffered saline (TBS) containing 
10% (v/v) normal donkey serum (Jackson ImmunoResearch Laboratories Inc., West 
Grove, PA, USA) and 0.1 % (v/v) Triton X-100 (Sigma-Aldrich) and subsequently 
incubated in appropriately diluted primary antibodies overnight at 4ºC.  After washing 
with TBS/0.025% Tween20, the primary antibodies were developed with diluted (1:200) 
Alexa Fluor 568 (anti-mouse) or Alexa Fluor 594 (anti-rabbit) conjugated secondary 
antibodies (Invitrogen) for 2 h at room temperature.  After rinsing, the sections were 
counterstained with Hoechst 33258 (Sigma-Aldrich) and mounted on Fluoromount 
(Sigma-Aldrich).  The following primary antibodies were used: Aβ deposits were 
stained with a mouse monoclonal anti-Aβ antibody (6E10; Covance; 1:1,000); 
astrocytes were stained with a mouse monoclonal anti-glial fibrillary acidic protein 
(GFAP) antibody (GA5; Millipore Corporation, Temecula, CA, USA; 1:200); microglia 
were stained with a rabbit polyclonal anti-Iba-I antibody (Wako Pure Chemicals, 
Richmond, VA, USA; 1:100); p-APP was stained with a rabbit polyclonal anti-p-APP 
(Thr668) antibody (Cell Signalling; 1:200); APP was stained with a rabbit polyclonal 
anti-APP, C-terminal antibody (Sigma-Aldrich; 1:200); p-tau was stained with a rabbit 
polyclonal anti-p-tau (Ser396) antibody (101815; Santa Cruz Biotechnology; 1:50); 
presynaptic terminals were stained with a mouse monoclonal anti-synaptophysin (SYN) 
antibody (SY38; Millipore; 1:100). 
 
Histochemistry 
After deparaffinization and rehydration, sections were stained with Thioflavin T, 
a highly sensitive marker of Aβ deposits. Staining was performed with freshly filtered 
0.05% Thioflavin T (Sigma-Aldrich) solution in PBS for 8 min at room temperature 
(Nunes et al., 2012). 
 
Image Analysis 
All images were captured using an Axioskop fluorescence microscope (Carl 
Zeiss GmbH, Hamburg, Germany).  At least eight images per hippocampal and cortical 
regions were acquired for each animal and converted to gray scale with an 8-bit format.  
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Semiquantitative analysis of GFAP, Iba-I, SYN and p-tau were performed with ImageJ 
1.46r software (National Institute of Health, Bethesda, MD, USA).  The background of 
each set of images was subtracted and a threshold optical density was determined and 
held constant.  Mean gray values (MGV) obtained for GFAP, Iba-I, SYN and p-tau 
immunostaining in the four mice groups were normalized to the MGV units of control wt 
mice and are presented as percentage of wt control mice.  The number of Aβ-plaques 
stained with Thioflavin T or 6E10 antibody were counted and presented as plaque 
number per square millimeter for both hippocampus and frontal cortex.  Measurement 
of amyloid (Thioflavin) and Aβ (6E10) burden were also performed in thresholded 
images by applying an unbiased computer-assisted image analyzer available in the 
ImageJ software, which was used to quantify the areas occupied by positive staining in 
the regions of interest.  Amyloid and Aβ burden was then calculated by normalizing the 
reactive area to the total area of the regions of interest, and is presented as percentage 
of the total area. 
 
Real-Time PCR 
Dissected hippocampus and frontal cortex were homogenized in TRIzol™ 
(Invitrogen) using a motor-driven Bio-vortexer (No1083; Biospec Products, Bartlesfield, 
OK).  After homogenization, total RNA was isolated according to the manufacturer’s 
protocol. Briefly, after homogenization in TRIzol, samples were maintained at room 
temperature for 5 min, followed by chloroform addition.  Samples were then vortexed 
and incubated at room temperature for 3 min.  Afterwards, samples were centrifuged at 
12000 g for 15 min at 4ºC, to separate the aqueous phase (containing RNA), 
interphase (DNA) and organic phase (proteins).  The aqueous phase was isolated to a 
new tube and isopropanol was added to precipitate RNA, while the organic phase – 
TRIzol-chloroform fractions – was further processed for protein extraction (see below).  
Samples were incubated for 2 h at -20ºC, followed by centrifugation at 12,000 g for 10 
min at 4ºC. The RNA pellet was then washed with 75% ethanol, centrifuged at 7,500 g 
for 5min at 4ºC.  Finally, the RNA pellet was allowed to dry for 5 min and further 
dissolved in autoclaved miliQ water.  Isolated RNA was quantified using a QubitTM 2.0 
fluorometer (Invitrogen).  Total RNA was converted into cDNA using Superscript II 
Reverse Transcriptase (Invitrogen) according to the manufacturer’s instructions.  
Quantitative Real-time PCR (qRT-PCR) analyses were performed in the 7300 Real-
Time PCR System (Applied Biosystems, Foster City, CA, USA), using SYBR Green 
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PCR master mix (Fermentas International Inc., Glen Burnie, Maryland, USA).  The 
expression levels of the genes of interest relative to the housekeeping gene 
Hypoxanthine-guanine Phosphoribosyltransferase (HPRT) were calculated using the 
ΔΔCt method.  Control wt mice were used as the calibrator and the relative changes in 
gene expression were calculated according to the formula 2-ΔΔCt.  Primer sequences 
are presented in Table 1. 
 
Table 1.  Primer sequences used to amplify indicated mouse cDNAs 
 Sense primer (5’-3’) Antisense primer (5’-3’) 
HPRT CAGTCCCAGCGTCGTGATTA TGGCCTCCCATCTCCTTCAT 
BACE1 TCCTTCCTCAGCAATACCTACG GGATGACTGTGAGACAGCGA 
TNFα GCCTCTTCTCATTCCTGCTTG CTGATGAGAGGGAGGCCATT 
IL-1β TGCCACCTTTTGACAGTGATG TGATGTGCTGCTGCGAGATT 
IL-6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA 
 
Total Protein Extraction 
Dissected hippocampus and frontal cortex were homogenized in TRIzol™ and 
total protein extracts were obtained from TRIzol-chloroform fractions, as described in 
(Simoes et al., 2013).  Basically, TRIzol-chloroform fractions were transferred for 2 ml 
tubes and 100% ethanol was added to precipitate DNA.  After mixing by inversion, the 
tubes were centrifuged at 2,000 g for 5 min at 4ºC.  The supernatant, containing the 
proteins, was transferred to new 2 ml tubes and the DNA pellet discarded.  
Subsequently, isopropanol was added and the samples were incubated for 10 min at 
room temperature.  Subsequently, samples were centrifuged at 12,000 g for 10 min 
and the supernatant discarded.  Finally, the protein pellets were washed three times 
with 0.3 M guanidine-HCl in 95 % ethanol.  In each wash, tubes were vigorously 
shaken until the pellets were dislodged from the tubes’ walls, incubated at room 
temperature for 20 min, and then followed by centrifugation of 7,500 g for 5 min at 4ºC.  
After the final wash and centrifugation, 100% ethanol was added, and samples 
incubated at room temperature for 20 min, followed by centrifugation at 7,500 g for 5 
min at 4ºC.  The supernatant was discarded and the protein pellet resuspended in 8 M 
Urea (in Tris-HCl 1 M, pH 8.0) and 1% SDS solution (1:1), followed by 5 cycles of 15 s 
ultrasonication, with 2-3 min ice incubation between each cycle (sonication adjusted to 
80% amplitude and 90% pulse – model UP100H, Hielscher Ultrasonics GmbH – 100 
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watts, ultrasonic frequency 30 Hz).  Finally, the samples were centrifuged at 3,200 g for 
10 min at 4ºC to sediment insoluble particles.  The supernatants, containing the 
solubilized proteins, were recovered and stored at -80ºC. 
 
Western Blot Analysis 
Total protein extracts from hippocampus and frontal cortex, obtained from 
TRIzol-chloroform fractions (see above) were used.  Protein concentrations were 
calculated using the Bio-Rad protein assay kit, according to the manufacturer’s 
recommendations.  Equal amounts of protein (60 μg) were electrophoretically resolved 
on denaturing 8 or 12% polyacrilamide gels.  To evaluate Aβ and APP levels with the 
corresponding cleavage products (sAPP-β and CTF-β), 60 μg of total protein extracts 
were electrophoretically separated in 10–20% Tris–Tricine gels (Bio-Rad).  The 
resolved proteins were transferred onto nitrocellulose membranes and blocking was 
performed with a 5% milk solution.  Membranes were then incubated overnight with the 
following primary antibodies: rabbit polyclonal anti-p-APP (Thr668) antibody (3823; Cell 
Signalling); rabbit polyclonal anti-APP, C-terminal antibody (A8717; Sigma-Aldrich); 
mouse monoclonal anti-Aβ antibody (6E10; Covance), used to detect both total Aβ 
peptide and CFT-β; mouse monoclonal antibody anti-sAPP-β fragment with the 
Swedish mutation (sAPP-β; 6A1; Immuno-Biological Laboratories, Inc, Minneapolis, 
MN, USA); mouse monoclonal anti-GFAP antibody (GA5; Millipore Corporation, 
Temecula, CA, USA); rabbit polyclonal anti-p-Akt (Ser473) antibody (7985; Santa Cruz 
Biotechnology); rabbit polyclonal anti-Akt (8312; Santa Cruz Biotechnology); rabbit 
polyclonal anti-p-GSK3α/β (Ser21/9) (9331; Cell Signalling); mouse monoclonal anti-
GSK3 α/β antibody (7219; Santa Cruz Biotechnology); rabbit polyclonal anti-p-tau 
(Ser396) (101815; Santa Cruz Biotechnology); mouse monoclonal anti-tau (tau5; 
58860; Santa Cruz Biotechnology).  In the next day, the membranes were incubated 
with goat secondary antibodies conjugated with horseradish peroxidase anti-mouse or 
anti-rabbit (BioRad Laboratories, Hercules, CA, USA) for 2 h at room temperature.  
After rinsing with TBS/0.2% Tween 20 three times (10 min each), the immunoreactive 
proteins were visualized with ImmobilonTM Western (Millipore) or SuperSignal West 
Femto substrate (Thermo Scientific).  Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (32233; Santa Cruz Biotechnology) or β-actin (AC-15; Sigma-Aldrich) were 
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used as loading controls.  Densitometric analyses were performed with the Image Lab 
software Version 5.1 Beta (Bio-Rad). 
 
Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) 
Sandwich ELISA kits (Millipore) were used to determine total Aβ1-40 and Aβ1-42 
concentrations from protein extracts of hippocampus and frontal cortex obtained from 
TRIzol-chloroform fractions.  TRIzol contains guanidine isothiocyanate, a strong 
denaturing agent, which allows for the disruption of aggregated Aβ and subsequent 
recovery of total Aβ present in both soluble and insoluble fractions.  The kits contain 
96-wells (divided in 12 strips with 8 wells each) coated with a monoclonal antibody 
specific for the C-terminal end of either Aβ1-40 or Aβ1-42.  In the first incubation step, 50 
μl of appropriately diluted protein lysates were added to the wells, along with a biotin 
conjugated antibody that binds the N-terminal epitope of the immobilized Aβ.  After 
orbital shaking for 5 min at 500 rpm/min, the samples were incubated overnight (16-
20h) at 4ºC, without shanking.  In the next day, solutions were decanted from the wells 
by tapping on paper, followed by washing of the wells 5 times with a washing solution.  
Afterwards, a peroxidase-streptavidin conjugate was added to each well for 30 min at 
room temperature on an orbital shaker (500 rpm), which allows the linking of 
peroxidase over a streptavidin-biotin bridge to the antibody-Aβ-antibody sandwich 
structure.  After another washing step as described above, a peroxidase substrate is 
added, which is then enzymatically processed into a blue colored product, with the 
color intensity being proportional to the quantity of Aβ contained in sandwich structures.  
Next, the samples were placed on an orbital shaker (500 rpm) until the development of 
blue color was visually detectable (5-10 min), followed by the addition of an acidic 
solution that stops the enzymatic reaction and turns the blue color into yellow.  Finally, 
absorbance was read at 450 nm in a microtiter plate reader (model 680, Bio-Rad), 
while absorbance at 590 nm was discounted as the baseline.  Aβ concentrations were 
calculated from the standard curves, which were processed in parallel with the brain 
samples. Two quality controls were also included, whose Aβ concentration values, as 
calculated from the standard curve, ought to fall within an expected range for the 
remaining quantifications obtained with the assay to be considered accurate. 
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Statistical Analysis 
Data comparisons were conducted with one-way analysis of variance (ANOVA) 
followed by post hoc Bonferroni’s test.  Differences between two groups were analyzed 
by Student’s two-tailed unpaired t test.  Behavioral data obtained with the Morris water 
maze were analyzed with 2-way ANOVA for repeated measures (RM), followed by 
Tukey post hoc test.  Analyses and graphical presentation were performed with the 
GraphPad Prism software Version 5 (GraphPad Software, Inc., San Diego, CA, USA).  
Results are presented as mean ± standard error of the mean (SEM). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III. RESULTS AND DISCUSSION 
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Short-term Treatment with TUDCA Attenuates Aβ Deposition in APP/PS1 
Mice 
APP/PS1 mice show increased Aβ production and parenchymal Aβ deposition 
beginning at 6 weeks of age, in the cortex, and at 2-3 months in the hippocampus 
(Radde et al., 2006).  In a previous study, we demonstrated that TUDCA treatment 
started at initial phases of Aβ accumulation significantly prevented amyloid plaque 
development (Nunes et al., 2012).  In the present study, we evaluated the effect of 
TUDCA on Aβ deposition when administrated after the onset of amyloid pathology in 
APP/PS1 mice, at 7 months of age.  Thioflavin T staining (Fig. 1A) and 6E10 
immunolabeling (Fig. 2A) revealed the presence of extensive amyloid deposits in the 
brains of APP/PS1 mice, which were not observed in wt mice.  Importantly, amyloid 
plaque number was significantly decreased in the hippocampus of TUDCA-treated 
transgenic mice when compared to control transgenic mice (p < 0.01), whereas no 
difference was observed in the frontal cortex (Fig. 1B).  Aβ immunohistochemistry 
further confirmed these results, showing ~ 50% reduction in Aβ plaque number in the 
hippocampus (p < 0.05) (Fig. 2B).  Moreover, amyloid burden, as evaluated by 
Thioflavin T (Fig. 1C) and 6E10 staining (Fig. 2C) was decreased in the hippocampus 
and frontal cortex of TUDCA-treated APP/PS1 mice by ~ 65 and 40%, respectively (p < 
0.05).  The cortex is the first brain region affected by Aβ deposition in this APP/PS1 
mouse model (Radde et al., 2006).  It has been demonstrated that cortical formation of 
new amyloid plaques in this model occurs until 4-5 months of age and greatly 
decreases after this period, while both newly formed and existing plaques appear to 
grow at a similar rate (Hefendehl et al., 2011).  Conversely, in the hippocampus, 
amyloid plaque formation only starts in the dentate gyrus at 2-3 months of age and in 
CA1 at 4-5 months of age (Radde et al., 2006), which might explain the differences 
observed in overall plaque burden and number between the frontal cortex and 
hippocampus with short-term TUDCA treatment (Fig. 1 and 2).  Taken together, these 
results demonstrate that TUDCA treatment attenuates brain Aβ deposition after the 
onset of amyloid pathology, particularly in the hippocampus of APP/PS1 mice. 
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Fig. 1 TUDCA treatment reduces 
amyloid plaque pathology in the 
brains of APP/PS1.  (A) 
Representative images of 
thioflavin staining in the 
hippocampus of control wt mice 
and hippocampus and frontal 
cortex of TUDCA-treated and 
untreated APP/PS1 mice. Scale 
bar, 100 μm.  (B) Quantification of 
amyloid plaque number per 
square millimeter in hippocampus 
and frontal cortex of TUDCA-
treated and control APP/PS1 
mice.  (C) Amyloid plaque burden 
presented as percentage of 
positive amyloid staining area 
relative to the total area of interest 
in hippocampus and frontal cortex 
of TUDCA-treated and untreated 
APP/PS1 mice.  Values represent 
mean ± SEM of 6-7 mice per 
group. †p < 0.01 and *p < 0.05 
from control APP/PS1 mice.  
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Fig. 2 TUDCA treatment reduces 
Aβ plaque pathology in the brains 
of APP/PS1 mice.  (A) 
Representative images of Aβ 
immunostaining (6E10) in the 
hippocampus of control wt mice 
and hippocampus and frontal 
cortex of TUDCA-treated and 
untreated APP/PS1 mice. Scale 
bar, 100 μm.  (B) Quantification of 
Aβ plaque number per square 
millimetre in hippocampus and 
frontal cortex of TUDCA-treated 
and control APP/PS1 mice. (C) 
Amyloid burden presented as 
percentage of positive Aβ 
immunoreactive area relative to 
the total area of interest in 
hippocampus and frontal cortex of 
TUDCA-treated and untreated 
APP/PS1 mice.  Values represent 
mean ± SEM of 6-7 mice per 
group.  *p < 0.05 from control 
APP/PS1 mice.  
 
 
 
 
 
 
 
 
 
TUDCA Reduces Amyloidogenic Processing of APP and Aβ Generation in 
APP/PS1 Mice 
We have reported that preventive TUDCA treatment diminishes amyloidogenic 
processing of APP in APP/PS1 mice, suggesting that Aβ reduction by TUDCA is the 
main mechanism underlying attenuated amyloid pathology (Nunes et al., 2012).  To 
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evaluate the effect of short-term treatment with TUDCA on the amyloidogenic 
processing of APP, we analyzed protein levels of APP β-secretase cleavage products, 
sAPP-β and CTF-β, by western blot (Fig. 3).  Notably, sAPP-β fragment was 
significantly decreased both in the hippocampus and frontal cortex (p < 0.05) of 
TUDCA-treated APP/PS1 mice as compared to control APP/PS1 mice, while full-length 
APP levels remained unchanged.  CTF-β levels were also reduced in the hippocampus 
(p < 0.01) and frontal cortex (p < 0.05) of TUDCA-treated transgenic mice when 
compared to controls.  In agreement, total Aβ was also significantly decreased in the 
hippocampus (p < 0.05) and, to a lesser extent, in the frontal cortex (p < 0.05) of 
TUDCA-treated APP/PS1 mice, indicating that short-term treatment with TUDCA 
reduces the amyloidogenic processing of APP even at later stages of amyloid 
pathology. 
 
Fig. 3 TUDCA treatment decreases the amyloidogenic processing of APP in the brains of 
APP/PS1 mice, as evaluated by the production of sAPP-β, CTF-β and Aβ.  Representative 
immunoblots of hippocampus and frontal cortex from control and TUDCA-treated wt and 
APP/PS1 mice with the respective densitometric analyses.  β-actin was used as loading control.  
Values are expressed as mean ± SEM of 6-7 mice per group.  †p < 0.01 and * p< 0.05 from 
control APP/PS1 mice. 
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We have also used sandwich ELISA to evaluate Aβ42 and Aβ40 levels in both 
brain regions of the four mice groups studied.  As expected, wt mice presented 
undetectable levels of either Aβ42 or Aβ40 (data not shown).  Further, we determined 
that both Aβ42 and Aβ40 levels were highly elevated in the brains of APP/PS1 mice, with 
Aβ42 exceeding Aβ40 by several-fold (Fig. 4).  Importantly, TUDCA treatment resulted in 
a significant reduction of both Aβ species in the hippocampus and frontal cortex of 
APP/PS1 mice, when compared to untreated transgenic mice (p < 0.05).  These 
findings indicate that TUDCA interferes with Aβ generation by reducing the 
amyloidogenic processing of APP, after the onset of the disease, thus representing a 
potential alternative for the existing therapeutic options.  
 
 
Fig. 4 TUDCA reduces Aβ42 and Aβ40 levels in the brains of APP/PS1 mice, as determined by 
ELISA.  Quantification of Aβ42 and Aβ40 levels in the hippocampus and frontal cortex of control 
and TUDCA-treated APP/PS1 mice.  Data are expressed as mean ± SEM of 6-7 mice per 
group.  * p< 0.05 from control APP/PS1 mice. 
 
TUDCA Supplementation Alters Akt/GSK3β Activities and Prevents tau 
Hyperphosphorylation in APP/PS1 Mouse Brains 
The Akt/GSK3 pathway is known to be deregulated in AD (Ryder et al., 2004; 
Malm et al., 2007; Lee et al., 2009; Durairajan et al., 2012).  The serine/threonine 
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kinase Akt is fully activated by phosphorylation at serine 473, after other downstream 
effects mediated by the phosphatidylinositol signalling pathway (Beaulieu et al., 2009).  
In turn, GSK3β is a substrate of Akt that is inhibited by phosphorylation of serine 9 
(Beaulieu et al., 2009).  In line with these findings, we determined the levels of 
phosphorylated Akt (p-Akt) and GSK3β (p-GSK3β) in brain lysates from TUDCA-
treated and untreated APP/PS1 mice.  Consistent with others (Durairajan et al., 2012), 
phosphorylation of Akt was significantly decreased in the frontal cortex of control 
APP/PS1 mice relative to wt mice (p < 0.05) (Fig. 5A).  Noteworthy, the reduction in p-
Akt levels was reverted in TUDCA-treated transgenic mice (p < 0.05), indicating 
increased activity of Akt with TUDCA treatment.  Unexpectedly, our results showed no 
significant differences between Akt phosphorylation levels in the hippocampus of 
control APP/PS1 and control wt mice.  In contrast, a trend to increase was observed in 
p-Akt levels of TUDCA-treated wt mice relative to control wt littermates, while a 
significant increase was detected between TUDCA-treated and control APP/PS1 mice 
(p < 0.05), indicating that TUDCA can specifically activate Akt in the hippocampus of wt 
mice.   
Regarding p-GSK3β levels, they were significantly reduced in both the 
hippocampus (p < 0.01) and frontal cortex (p < 0.005) of control transgenic mice 
relative to wt controls (Fig. 5B).  Importantly, TUDCA treatment reverted the reduction 
observed in p-GSK3β levels in APP/PS1 mice for both brain regions analyzed (p < 
0.005).  Our findings suggest that TUDCA may abrogate AD-associated GSK3β 
dysregulation, probably by specifically activating the upstream Akt signalling pathway. 
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Fig. 5 TUDCA treatment increases Akt and GSK3β phosphorylation levels in the brains of 
APP/PS1 mice.  (A) Representative immunoblots of p-Akt (Ser473) and total Akt in the 
hippocampus and frontal cortex of control and TUDCA-treated wt and APP/PS1 mice, and 
respective densitometric analyses of the p-Akt/Akt ratio. (B) Representative immunoblots of 
p-GSK3β (Ser9) and total GSK3β in the hippocampus and frontal cortex of control and TUDCA-
treated wt and APP/PS1 mice with the respective densitometric analyses of the p-
GSK3β/GSK3β ratio.  Values are expressed as mean ± SEM of 6-7 mice per group.  *p < 0.05, 
†p < 0.01 and ‡ p< 0.005 from control wt mice and §p < 0.05 and ¶p < 0.01 from control 
APP/PS1 mice. 
 
Interestingly, it has recently been reported that specific GSK3β inhibition 
resulted in decreased BACE1 mRNA expression and protein levels in an AD mouse 
model (Ly et al., 2013).  Other authors have also described increased levels of BACE1 
in AD patient brains (Yang et al., 2003).  Taking this into account, we evaluated if 
TUDCA modulation of the amyloidogenic processing of APP was correlated with the 
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bile acid effect on GSK3β activity and, subsequently, BACE1 expression levels.  
However, this was not the case since no changes were detected in BACE1 levels after 
TUDCA treatment, at both mRNA and protein levels (Fig. 6). 
 
Fig. 6 TUDCA treatment does not affect BACE1 mRNA and protein levels in the brains of 
APP/PS1 mice.  (A) BACE1 mRNA levels in the hippocampus and frontal cortex of control and 
TUDCA-treated wt and APP/PS1 mice, as determined by qRT-PCR.  *p < 0.05 from control wt 
mice (n = 6-7 mice per group).  (B) Representative immunoblots of BACE1 in hippocampus and 
frontal cortex from control and TUDCA-treated wt and APP/PS1 mice with the respective 
densitometric analyses.  GAPDH was used as loading control.  Values are expressed as mean 
± SEM of 6-7 mice per group. 
 
Alternatively, other studies in vitro and in vivo suggest that GSK3β is able to 
phosphorylate APP at threonine 668 (p-APP), which increases Aβ production (Aplin et 
al., 1996; Lee et al., 2003; Durairajan et al., 2012)  Therefore, we hypothesized that the 
effect of TUDCA on GSK3β activity impacts on APP phosphorylation levels.  
Immunoblot analyses revealed that p-APP levels were increased in the frontal cortex of 
APP/PS1 mice comparing to wt mice (p < 0.05); however, they were unaffected by 
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TUDCA treatment (Fig. 7A).  We further analyzed APP phosphorylation by 
immunohistochemistry and observed extensive accumulation of p-APP in dystrophic 
neurites closely associated with amyloid plaques, while total APP immunoreactivity was 
detected in both dystrophic neurites and neuronal perikaria (Fig. 7B).  However, no 
changes were detected with TUDCA (Fig. 7B).  These results are in agreement with 
previous studies in AD patient brains and in mouse models (Lee et al., 2003) (Shin et 
al., 2007).  Curiously, p-APP immunoreactivity around amyloid plaques was more 
extensively detected in the frontal cortex than in the hippocampus of APP/PS1 mice 
(Fig. 7B). 
Fig. 7 TUDCA treatment does 
not alter APP phosphorylation 
in the brains of APP/PS1 
mice.  (A) Representative 
immunoblots of p-APP 
(Thr668) and total APP in 
hippocampus and frontal 
cortex lysates from control 
and TUDCA-treated wt and 
APP/PS1 mice with the 
respective densitometric 
analyses of the ratio 
p-APP/APP.  Values are 
expressed as mean ± SEM of 
6-7 mice per group.  *p < 0.05 
from control wt mice.  (B) 
Fluorescent microscopy of 
amyloid plaques (thioflavin T-
green) and APP or p-APP 
(red) in control and TUDCA-
treated APP/PS1 mice.  Cell 
nuclei were counterstained 
with Hoechst 33583 (blue).  
Unlike p-APP staining, which 
was mostly associated with 
dystrophic neurites located 
close to amyloid plaques, 
total APP was also 
extensively detected in neuronal perikarya (arrowheads).  Scale bar, 25 μm.  
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In respect to tau, it is known that the APP/PS1 mouse model used in this study 
present hyperphosphorylated tau-positive neuritic structures located in the proximity of 
amyloid plaques at 8 months of age, with no significant NFT formation (Radde et al., 
2006).  Since GSK3β is one of the major kinases implicated in tau 
hyperphosphorylation (Li and Paudel, 2006; Leroy et al., 2010), we evaluated whether 
TUDCA-dependent inhibition of GSK3β was affecting p-tau levels.  Tau 
phosphorylation was determined by immunoblotting and immunohistochemistry using 
an antibody against tau phosphorylated at Ser396 (corresponding to Ser936 of mouse 
origin), a residue already identified as being specifically phosphorylated by GSK3β in 
the absence of priming events (Li and Paudel, 2006; Leroy et al., 2010).  As depicted in 
Fig. 8A, p-tau levels were increased ~2-fold in both hippocampus and frontal cortex 
(p < 0.05) of APP/PS1 mice relative to control wt mice.  In contrast, TUDCA-treated 
transgenic animals presented a strong reduction in p-tau levels in both brain regions, 
showing a decrease of ~ 40% relative to control APP/PS1 mice (p < 0.05).  
Immunohistochemical analyses further revealed the presence of phosphorylated tau 
associated with dystrophic neurites surrounding amyloid plaques (Fig. 8B).  
Quantification of phosphorylated tau immunoreactivity further confirmed these results, 
supporting the view that the inhibitory effect of TUDCA on GSK3β activity positively 
impacts on tau hyperphosphorylation.   
 
TUDCA Treatment Ameliorates Astrocytosis and Microgliosis in APP/PS1 
Mice 
Amyloid deposition leads to extensive microgliosis and astrocytosis surrounding 
the affected areas in AD patients and mouse models (Selkoe, 2001; Meraz-Rios et al., 
2013).  We have already described that TUDCA supplementation mitigates the 
activation of glial cells in APP/PS1 mice (Nunes et al., 2012).  Interestingly, GSK3β is 
emerging as a key enzyme involved in the regulation of pathways and transcription 
factors involved in microglial and astrocytic activation (Yuskaitis and Jope, 2009; 
Beurel and Jope, 2010; Koistinaho et al., 2011).  Due to the multiple lines of evidence 
showing a TUDCA-dependent effect on both GSK3β phosphorylation levels and glial 
activation, we assessed astrocytosis by GFAP immunostaining and immunoblot  
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Fig. 8 TUDCA treatment 
reduces tau phosphorylation 
in the brains of APP/PS1 
mice.  (A) Representative 
immunoblots of p-tau (Ser396) 
and total tau in the 
hippocampus and frontal 
cortex of control and TUDCA-
treated wt and APP/PS1 mice 
with the respective 
densitometric analyses of the 
p-tau/tau ratio.  (B) Double 
staining of p-tau (red) and 
amyloid plaques (thioflavin T - 
green) in the hippocampus 
and frontal cortex of control 
and TUDCA-treated APP/PS1 
mice.  Scale bar, 25 μm.  (C) 
Quantification of p-tau mean 
gray values in the 
hippocampus and frontal 
cortex of control and TUDCA-
treated APP/PS1 mice, 
presented as percentage of 
control APP/PS1 mice.  
Values are expressed as 
mean ± SEM of 6-7 mice per 
group.  *p < 0.05 from control 
wt mice and †p < 0.05 and 
§p < 0.01 from control 
APP/PS1 mice. 
 
analyses, and microgliosis by Iba-I immunostaining.  As expected, GFAP 
immunofluorescence showed a prominent increase of reactive astrocytes in the 
hippocampus (p < 0.01) and frontal cortex (p < 0.005) of control APP/PS1 mice 
compared to control wt mice (Fig. 9A and B).  Noteworthy, GFAP-reactive astrocytes 
were significantly reduced in both brain regions of TUDCA-treated APP/PS1 mice 
compared to APP/PS1 controls (p < 0.05).  Additionally, GFAP protein levels were also 
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evaluated by immunoblot, further confirming the dramatic increase in GFAP levels in 
the hippocampus (p < 0.005) and frontal cortex (p < 0.001) of control transgenic mice, 
when compared to control wt mice (Fig. 9C).   
 
Fig. 9 TUDCA treatment 
attenuates astrogliosis in the brains 
of APP/PS1 mice.  (A) 
Representative images of GFAP 
immunostaining in the 
hippocampus of control wt mice 
and hippocampus and frontal 
cortex of control and TUDCA-
treated APP/PS1 mice. Scale bar, 
25 μm.  (B) Quantification of GFAP 
mean gray values in the 
hippocampus and frontal cortex of 
control and TUDCA-treated wt and 
APP/PS1 mice, presented as 
percentage of control wt mice.  (C) 
Representative immunoblots of 
GFAP in hippocampus and frontal 
cortex lysates from control and 
TUDCA-treated wt and APP/PS1 
mice with the respective 
densitometric analyses.  GAPDH 
was used as loading control.  
Values are expressed as mean ± 
SEM of 6-7 mice per group.  †p < 
0.01, ‡p < 0.005 and §p < 0.001 
from control wt mice and *p < 0.05 
from control APP/PS1 mice. 
 
 
 
 
 
 
61 
 
Moreover, our results revealed a ~ 30% decrease in GFAP levels in the 
hippocampus and 45% in the frontal cortex of TUDCA-treated APP/PS1 mice relative 
to APP/PS1 controls (p < 0.05), further corroborating the results obtained for GFAP 
immunostaining (Fig. 9C). 
Microgliosis was significantly elevated in the hippocampus and frontal cortex of 
control transgenic mice relative to wt mice (p < 0.005) (Fig. 10A and B).  Importantly, 
TUDCA treatment of APP/PS1 animals decreased Iba-I immunofluorescence in both 
hippocampus and frontal cortex (p < 0.01).  Since reactive microglia are usually tightly 
clustered around amyloid deposits, we performed double immunohistochemical 
staining with Iba-I and Thioflavin, to evaluate the effect of TUDCA in amyloid-
dependent microgliosis.  In accordance with previous reports, clusters of hypertrophic 
microglia were detected in close proximity to Aβ plaques in the brains of control 
APP/PS1 mice, while less reactive microglia were visualized surrounding amyloid 
plaques in the parenchyma of TUDCA-treated transgenic mice (Fig. 10C). 
To further characterize the effect of TUDCA on the pro-inflammatory response, 
we analyzed by qRT-PCR the expression levels of TNF-α, IL-1β and IL-6, pro-
inflammatory cytokines extensively described as being augmented in AD (Meraz-Rios 
et al., 2013).  As anticipated, the mRNA levels of all three cytokines were significantly 
elevated in both hippocampus and frontal cortex of control APP/PS1 mice when 
compared to control wt mice (Fig. 11), with TNF-α mRNA in the frontal cortex 
presenting the highest increase (~ 11-fold, p < 0.0001). TNF-α mRNA levels were 
significantly decreased by TUDCA treatment both in the hippocampus (p <0.05) and in 
the frontal cortex (p < 0.005) of APP/PS1 mice relative to control APP/PS1 mice.  IL-1β 
and IL-6 mRNA levels showed no significant differences or a trend to decrease 
between these two groups. These results further indicate that TUDCA reduces 
neuroinflammation in APP/PS1 mice. 
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Fig. 10 TUDCA treatment reduces 
microgliosis in the brains of 
APP/PS1 mice.  (A) 
Representative images of Iba-I 
immunostaining in the 
hippocampus of control wt mice 
and hippocampus and frontal 
cortex of control and TUDCA-
treated APP/PS1 mice. Scale bar, 
25 μm.  (B) Quantification of Iba-I 
MGV in the hippocampus and 
frontal cortex of control and 
TUDCA-treated wt and APP/PS1 
mice, presented as percentage of 
control wt mice.  Values are 
expressed as mean ± SEM of 6-7 
mice per group.  †p < 0.005 from 
control wt mice and *p < 0.01 from 
control APP/PS1 mice.  (C) 
Double staining of Iba-I and 
amyloid plaques (thioflavin T 
staining) in the hippocampus of 
control and TUDCA-treated 
APP/PS1 mice.  Scale bar, 25 μm 
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Fig. 11 TUDCA treatment decreases TNF-α 
mRNA expression in the hippocampus and 
frontal cortex of APP/PS1 mice.  
Quantification of TNF-α, IL-1β and IL-6 
mRNA levels in the hippocampus and frontal 
cortex of control and TUDCA-treated wt and 
APP/PS1 mice.  Data are expressed as 
mean ± SEM of 6-7 mice per group.  
*p < 0.01, †p < 0.005, ‡p < 0.001 from 
control wt mice and §p < 0.05 and ¶p < 0.005 
from control APP/PS1 mice. 
 
 
 
 
 
 
 
 
TUDCA treatment reduces synaptic loss in APP/PS1 mice 
Aβ species and extensive gliosis have been widely implicated in the 
neurodegenerative processes observed during AD progression.  However, several 
transgenic mouse models of AD only manifest global neuronal loss at very advanced 
ages (~ 17 months of age) (Wirths and Bayer, 2010).  Further, the APP/PS1 mouse 
model used in this study only manifest a modest but significant neuron loss (11%) at 17 
months of age in high neuronal density subregions, such as the granule cell layer of the 
dentate gyrus (Rupp et al., 2011).  Furthermore, most neurons that present dystrophic 
axons associated with amyloid plaques are still viable (Adalbert et al., 2009).  These 
features thus render our mouse model inappropriate to study the anti-apoptotic 
properties of any given substance in AD (Radde et al., 2006; Rupp et al., 2011).  On 
the other hand, several animal models present loss of presynaptic terminals, as 
determined by SYN immunostaining and protein levels (Radde et al., 2006; Ding et al., 
2008; Nunes et al., 2012).  Interestingly, soluble Aβ oligomers are widely accepted as 
the main neurotoxic species, directly contributing to loss of synaptic integrity and 
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subsequently to memory impairment and cognitive deficits (Selkoe, 2002).  Synapse 
loss starts as early as at 5 months of age in the hippocampal dentate gyrus (Ding et al., 
2008), indicating that APP/PS1 mice models mimic the progression of synaptic 
dysfunction that is observed early in patients with very mild to mild AD (Masliah et al., 
2001; Selkoe, 2002).  The hippocampal dentate gyrus is highly enriched in synaptic 
connections between the mossy fibers of the dentate gyrus and the dendrites of the 
pyramidal neurons; further, the synaptic connections of this brain region are commonly 
affected in APP/PS1 mice in an age-related manner, even in regions devoid of amyloid 
plaques, which is thought to relate to the development of memory deficits usually 
observed in these models (Rutten et al., 2005; Ding et al., 2008).  Consequently, we 
proceeded to evaluate synaptic integrity in the dentate gyrus by SYN immunostaining.  
As anticipated, semiquantitative analysis of SYN immunostaining revealed an 
accentuated decrease in SYN immunoreactivity in the polymorphic layer of the dentate 
gyrus of control APP/PS1 mice relative to control wt mice (p < 0.005), while TUDCA 
treatment partially reverted this phenotype in APP/PS1 mice (p < 0.05) (Fig. 12).  
These data indicate that TUDCA administration even after the onset of AD pathology 
can still partially protect from loss of synaptic function. 
 
Fig. 12 TUDCA treatment partially rescues loss of presynaptic terminals.  (A) Representative 
images of SYN immunostaining in the hippocampus of control and TUDCA-treated wt and 
APP/PS1 mice.  Scale bar, 25 μm.  (B) Quantification of SYN mean gray values in the 
hippocampus of control and TUDCA-treated wt and APP/PS1 mice, presented as percentage of 
control wt mice.  Values are mean ± SEM of 6-7 mice per group.  †p < 0.005 from control wt 
mice and *p < 0.05 from control APP/PS1 mice. 
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APP/PS1 double-transgenic mice undergo memory deterioration due to the 
age-associated progression of Aβ pathology (Radde et al., 2006).  To evaluate whether 
TUDCA administration ameliorates memory deficits in aged APP/PS1 mice, all animals 
were trained in the Morris water maze.  During training, we measured no significant 
differences between groups.  All groups learned to locate the hidden platform position 
over consecutive training days (Two-way RM ANOVA: F9, 351 = 82.96, p < 0.001) and 
showed similar learning curves (Fig. 13A).  During the second probe trial, we removed 
the platform and measured the time mice spent in each of the different quadrants.  We 
found a significant quadrant (Two-way RM ANOVA: F3, 117 =24.59, p < 0.001) and 
quadrant by group effect (F9, 117 = 2.144, p < 0.05).  Post hoc test shows that both wt 
groups spent a significant amount of time in the target quadrant (p < 0.001), whereas 
such a target quadrant preference is lacking in control APP/PS1 mice (Fig. 13B).  
Nevertheless, a trend to improved memory was detected, which probably correlates 
with TUDCA-dependent attenuation of Aβ pathology. 
 
Fig. 13 Cognitive performance in the Morris water maze in vehicle and TUDCA-treated wt and 
APP/PS1 mice.  (A) During training, no significant group differences were measured in time to 
find the hidden platform.  All groups showed similar learning curves.  (B) During the second 
probe trial, we found a significant target quadrant preference in both control and TUDCA-treated 
wt mice.  Such preference was not found in control APP/PS1 mice.  TUDCA-treated APP/PS1 
mice showed a trend to target quadrant preference, albeit not significant (n = 10 control wt mice; 
n = 8 TUDCA-treated wt mice; n = 11 control APP/PS1 mice; and n = 14 TUDCA-treated 
APP/PS1 mice).  Data are expressed as means ± SEM. *p < 0.001 between target quadrant 
and all other quadrants; †p < 0.05 between target quadrant and A1 quadrant and ‡ p < 0.01 
between target quadrant and opposite quadrant. A1 and A2: adjacent quadrants, O: opposite 
quadrant, T: target quadrant. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV. DISCUSSION 
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AD is the most prevalent neurodegenerative disorder in ageing populations 
worldwide.  Available treatments are mostly symptomatic and unable to arrest or revert 
the progression of the disease (Reitz and Mayeux, 2014).  In this regard, we have 
recently described a remarkable rescue of different memory types, as well as improved 
synaptic efficiency in APP/PS1 transgenic mice long-term treated with neuroprotective 
TUDCA (Nunes et al., 2012; Lo et al., 2013; Ramalho et al., 2013). Now, we extended 
our studies and further demonstrated the therapeutic efficacy of TUDCA when 
administrated at 7 months of age, after the onset of amyloid pathology.  The relevance 
of using transgenic mouse models to study AD has raised several concerns, since 
most of the clinical trials using AD therapeutic agents tested in mice result in negative 
therapeutic outcomes (Kokjohn and Roher, 2009).  Nevertheless, animal models, 
including APP/PS1 mice, remain instrumental for dissecting the molecular pathways 
involved in AD and evaluating new therapeutic avenues in vivo. 
Notably, our results suggest that, although TUDCA treatment does not 
completely revert amyloid pathology after its establishment, this bile acid can still 
attenuate the progression of Aβ deposition, as confirmed by the diminished production 
of APP cleavage fragments and decrease of total Aβ levels in the hippocampus and 
frontal cortex of APP/PS1 mice. 
We showed that Akt activity was reduced in the frontal cortex of APP/PS1 mice 
relative to control littermates, while no significant changes were observed in the 
hippocampus.  However, GSK3β was hyperactivated in both brain regions, which 
indicates that hippocampal GSK3β deregulation is probably independent of the 
upstream Akt pathway.  Although unexpected, the absence of differences in Akt 
phosphorylation levels in the hippocampus, with a concomitant decrease in GSK3β 
phosphorylation between wt and APP/PS1 mice has also been demonstrated by others 
in APP/PS1 mice at 16 months of age (Malm et al., 2007).  Controversially, other 
studies have reported a reduction in both Akt and GSK3β phosphorylation levels in the 
hippocampus of 6 and 13 months-old APP/PS1 mice (Hu et al., 2013; Jia et al., 2013).  
Interestingly, AD patients appear to present reduced Akt phosphorylation in 
hippocampal neurons only at end stages of disease, when altered Akt activity is 
already established in the cortex (Griffin et al., 2005; Lee et al., 2009).  This 
observation has been extended in other reports that detected reduced phosphorylation 
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of Akt in AD brain, along with GSK3 hyperactivity (Lee et al., 2009; Liu et al., 2011).  
This feature is widely mimicked in vivo by AD transgenic mouse models, and in in vitro 
by cell models harbouring familial AD mutations (Ryder et al., 2004; Durairajan et al., 
2012; Jia et al., 2013; Jimenez et al., 2011;).  Taken together, it is possible that 
hippocampal Akt deregulation correlates with affected neuronal integrity in this brain 
region, which can be detected in transgenic mice only several months after the 
development of other AD-related features. 
We have previously shown that TUDCA can activate the PI3K/Akt signalling 
pathway, resulting in neuronal protection against Aβ toxicity (Sola et al., 2003).  It is 
therefore plausible that the increased Akt phosphorylation levels detected in TUDCA-
treated APP/PS1 and wt mice depends on the activation of upstream PI3K. However, 
the role of PI3K/Akt signalling in AD remains controversial.  Several reports implicate 
insulin resistance as a probable mechanism towards impaired PI3K/Akt signalling and 
subsequent alterations in neuronal function, metabolism and survival (Liu et al, 2011; 
de la Monte, 2012; Lee et al, 2009).  In fact, AD brain analyses revealed impaired 
insulin downstream signalling involving abnormal IRS-1 serine phosphorylation 
patterns that were correlated with reduced PI3K and/or Akt activity (Liu et al.,2011; Lee 
et al., 2009; Bomfim et al., 2012).  Curiously, AD patients with type 2 diabetes 
presented a more severe reduction in the activity of insulin/PI3K/Akt than AD or 
diabetes patients, suggesting that deficient brain insulin signalling may precede AD and 
contribute to the progression of the disease (Liu et al., 2011).  This observation further 
implicates diabetes as a risk factor for AD, and downstream PI3K/Akt inactivation might 
be involved in this process.  
Interestingly, insulin-deficient diabetic mice also develop cognitive deficits and 
impaired memory, which is strongly correlated with decreased IR, Akt and GSK3 
phosphorylation levels in the brain (Jolivalt et al., 2008).  Moreover, mounting evidence 
suggest that soluble Aβo can bind to IR and block its activation, thus reducing insulin 
downstream signalling (Zhao et al., 2008; De Felice et al., 2009; Moloney et al., 2010).  
Aβ can also impair insulin signalling by activating TNF-α/JNK, which leads to abnormal 
IRS-1 phosphorylation and activity (Bomfim et al., 2008; Jia et al., 2013).  Importantly, 
this was reported in an APP/PS1 mouse model that develops brain insulin resistance 
due to abnormal IRS-1 phosphorylation mediated by TNF-α/JNK.  Moreover, treatment 
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with a natural polyphenol significantly reduced JNK activity and TNF-α levels, reverting 
PI3K/Akt/GSK3β signalling impairment and ameliorating cognitive deficits (Jia et al., 
2013). These observations place Aβ pathology above insulin/PI3K/Akt deregulation. 
Since we have also detected reduced levels of TNF-α in the brains of TUDCA-treated 
APP/PS1 mice, it is tempting to speculate that this could be correlated with decreased 
JNK activation and, subsequently, with higher activity of the IRS-1/PI3K/Akt pathway.  
TUDCA can also downregulate Aβ-driven JNK activity, which further strengthen this 
hypothesis (Viana et al, 2010). 
Conversely, others suggested that abnormal upregulation of the PI3K/Akt 
pathway in AD brain can lead to insulin resistance by feedback mechanisms, as well as 
other AD pathologies (Talbot et al, 2012; O’Neill, 2013).  It has been suggested that 
one of the major mechanisms by which PI3K/Akt mediates AD progression, depends 
on mTOR activation and subsequent decrease in autophagy and upregulation of tau 
and APP expression (O’Neill, 2013).  In this regard, further analyses should be 
performed to dissect the contribution of PI3K/Akt in the present study. Evaluation of IR 
levels, IRS1 and 2 patterns of phosphorylation, activation of JNK by phosphorylation, 
as well as other downstream events, such as Akt-mediated phosphorylation of mTOR 
and autophagy, would contribute to further characterize the insulin/PI3K/Akt pathway in 
APP/PS1 mice and its modulation by TUDCA (Talbot et al, 2012; O’Neill, 2013). 
Importantly, the role of TUDCA treatment in the modulation of Akt/GSK3β 
signalling was highlighted by the reversion of altered Akt/GSK3β levels in the cortex, 
and GSK3β in the hippocampus, to control levels, suggesting a therapeutical effect.  
Moreover, inhibition of GSK3β activity correlated with a reduction in tau 
hyperphosphorylation levels at Ser396, suggesting that inactivation of GSK3β by 
TUDCA positively modulates AD-associated tau pathology.   
Although GSK3β has been also widely accepted as a major player in several 
pathological mechanisms associated with AD, the mechanism by which this kinase 
regulates cerebral amyloidosis is still somewhat controversial. Some authors have 
reported that GSK3β inhibition downregulates BACE1 gene expression in APP23/PS45 
double transgenic mice (Ly et al., 2013), while others did not detected significant 
alterations in BACE1 protein levels (Ding et al., 2008; Durairajan et al., 2012).  This 
discrepancy might be attributable to differences between the animal models used or 
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the ages at which the animals were engaged in the respective studies.  Surprisingly, no 
significant changes were detected in BACE1 mRNA and protein levels between 
APP/PS1 mice and wt littermates, treated or untreated with TUDCA 
GSK3β also appears to be involved in the phosphorylation of APP at the 
cytoplasmic residue Thr668, which is thought to elevate Aβ generation (Aplin et al., 
1996; Lee et al., 2003; Chang et al., 2006; Durairajan et al., 2012).  In this respect, we 
evaluated whether the effect of TUDCA on APP processing was dependent on the 
regulation of GSK3β-dependent APP phosphorylation.  Immunoblot analysis revealed 
increased p-APP levels solely in the cortex of APP/PS1 mice, which was not altered by 
TUDCA administration.  Still, there are other kinases deregulated in AD pathology, 
such asCDK5 and JNK, that are postulated to phosphorylate APP, which might explain 
the unaltered p-APP levels despite GSK3β inhibition (Durairajan et al., 2012).  Several 
studies suggest that APP phosphorylation targets the protein for fast axonal transport 
to the nerve terminals.  Increased co-localization of APP with β- and γ-secretases 
within axonal or presynaptic vesicles culminates in enhanced Aβ generation (Lee et al., 
2003; Lee et al., 2005; Durairajan et al., 2012).  In fact, p-APP immunoreactivity was 
mostly associated with dystrophic neurites located around amyloid plaques, while total 
APP immunoreactivity was observed in both dystrophic neurites and neuronal 
perikarya in the brains of APP/PS1 mice, indicating that p-APP is preferably located in 
axonal regions.  Interestingly, p-APP immunoreactivity was more pronounced around 
amyloid plaques located in the frontal cortex than in those located in the hippocampus, 
indicating that the increase in p-APP levels as determined by immunoblot analysis in 
the frontal cortex probably derives from extensive p-APP accumulation around amyloid 
plaques.  Increased p-APP levels in the cortex of APP/PS1 mice relative to the 
hippocampus are probably associated with the earlier onset of amyloid deposition 
observed in the cortex, although a region specific effect cannot be excluded.  These 
findings indicate that TUDCA treatment does not influence APP processing by 
modulating BACE1 protein levels or APP phosphorylation levels. 
Other aspect of GSK3 inhibition is the associated decrease of glial activation 
and overall neuroinflammatory markers (Yuskaitis and Jope, 2009; Beurel and Jope, 
2010; Koistinaho et al., 2011).  In this context, GSK3β appears to upregulate the 
expression of several pro-inflammatory mediators, such as TNF-α (Yuskaitis and Jope, 
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2009; Wang et al., 2010), while decreasing anti-inflammatory molecules (Koistinaho et 
al., 2011).  Moreover, GSK3β inhibition reduces microglial activation and migration 
(Yuskaitis and Jope, 2009), and increases inflammatory tolerance in astrocytes upon 
repeated inflammatory stimuli, suggesting a paramount role for this kinase during 
chronic neuroinflammation (Beurel and Jope, 2010).  As expected, a marked 
neuroinflammatory phenotype was evident in the brains of APP/PS1, with a significant 
increase in gliosis and upregulation of pro-inflammatory TNF-α, IL-1β and IL-6.  
Importantly, TUDCA administration after the onset of amyloid pathology significantly 
ameliorated astrocytosis and microgliosis in both hippocampus and frontal cortex of 
APP/PS1 mice, and specifically inhibited TNF-α mRNA expression.  These results are 
in agreement with others showing decreased levels of TNF-α mRNA in activated 
astrocytes treated with GUDCA but no alterations in IL-1β expression (Fernandes et 
al., 2007).  More importantly, anti-TNF-α therapeutic strategies were reported to reduce 
amyloid deposition, gliosis and tau hyperphosphorylation, rescuing cognitive and 
memory deficits in AD transgenic mice (Shi et al., 2011; Tweedie et al., 2012).  In 
addition, intrinsic anti-inflammatory properties have also been attributed to TUDCA, 
which may explain the striking results obtained for astrocytosis and microgliosis in our 
model.  TUDCA has been shown to decrease glial activation and microglial migration in 
acute neuroinflammation models both in vivo and in vitro (Yanguas-Casas et al., 2014).  
Finally, TUDCA has also been reported to inactivate GSK3β and reduce inflammation 
in liver tissue obtained after partial hepatectomy (Ben Mosbah et al., 2010). 
Other studies also showed the anti-inflammatory properties of bile acids similar 
to TUDCA, such as ursodeoxycholic acid and GUDCA, in astrocytes and microglia 
exposed to pro-inflammatory stimuli including Aβ (Joo et al., 2003; Fernandes et al., 
2007).  Since Aβ accumulation is the main mechanism involved in glial activation 
during AD (Radde et al., 2006; Meraz-Rios et al., 2013), and GSK3β is also potentially 
involved, we suggest that TUDCA-mediated effects on Aβ load, GSK3β activity and 
TNF-α expression are responsible for the reduced neuroinflammatory conditions in 
TUDCA-treated APP/PS1 mice.  In this regard, we are currently elucidating the 
molecular mechanisms by which TUDCA protects from glial activation. 
Activation of PI3K/Akt signalling is also crucial for the expression of late-phase 
long-term potentiation (LTP), a form of synaptic plasticity that is closely related with 
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learning and memory, and specifically affected in AD (Selkoe, 2002; Horwood et al., 
2006).  This effect is particularly important in the dentate gyrus of the hippocampus 
(Karpova et al., 2006).  Impairments in LTP may eventually culminate in synaptic 
depression that in turn is correlated with structural changes in synaptic morphology 
(Selkoe, 2002).  Aβ oligomers also inhibit LTP and destabilize synaptic connection 
(Selkoe, 2002).  Importantly, treatment with TUDCA resulted in a reduction of 
presynaptic terminals loss, as evidenced by an increase in the presynaptic marker 
synaptophysin in the dentate gyrus of APP/PS1 mice.  This effect probably derives 
from the decrease in Aβ load, although activation of PI3K/Akt cannot be excluded.  
However, only a trend to improved spatial memory was detected in TUDCA-treated 
APP/PS1 mice compared to control APP/PS1 mice.  Since this mouse model already 
presents extensive cognitive deficits and memory impairment at 7-8 months of age 
(Radde et al., 2006; Serneels et al., 2009), it is likely that TUDCA treatment started at 7 
months is not sufficient to revert emerging or pre-established cognitive deficits.  Still, 
mouse models do not develop the same type of cognitive decline usually observed in 
AD patients (Webster et al., 2014), which may also influence the behavioral data. 
In conclusion, our results demonstrate the therapeutic efficacy of TUDCA in 
APP/PS1 mice with established amyloid pathology by attenuating Aβ production and 
deposition, tau pathology, glial activation and loss of synaptic function.  Most of these 
effects are likely related to the activation of the Akt/GSK3β signalling pathway.  
However, modulation of Aβ deposition may influence several pathways that impact on 
tau hyperphosphorylation and neuroinflammation, which implicates that the reduction 
observed in Aβ load after TUDCA treatment may alter these AD-phenotypic traits by 
GSK3β-independent pathways.  Finally, since chronic neuroinflammation is also 
strongly associated with accelerated AD progression, the anti-inflammatory properties 
of TUDCA further highlight its therapeutic potential.  These evidences, allied to its 
safety and brain bioavailability, point TUDCA as a promising therapeutic strategy to 
attenuate AD progression. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V. CONCLUSION AND FUTURE PERSPECTIVES 
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The present work further expanded previous in vitro and in vivo studies 
regarding the therapeutic potential of TUDCA in AD.  Here, we demonstrated that 
TUDCA treatment administrated to APP/PS1 mice after the onset of amyloid pathology 
decreases Aβ production and deposition, tau hyperphosphorylation and gliosis, while 
partially protecting against synaptic loss.  Importantly, several of these effects might be 
connected to modulation of the Akt/GSK3β pathway.  These results support the view 
that TUDCA can act as a multi-targeted strategy to treat several pathologies associated 
with AD progression. 
Still, further work is needed in order to clarify the full range of TUDCA 
therapeutic targets. 
One of the main questions concerns TUDCA-dependent modulation of the 
amyloidogenic processing of APP.  Regarding this question, we are currently engaged 
in the optimization of a murine neuroblastoma cell model that overexpresses mutated 
APP to further evaluate the effect of TUDCA on the proteolysis of this protein.  First, we 
intend to determine whether TUDCA modulates the intracellular trafficking of APP and 
its cleavage fragments by performing subcellular fractionation techniques, which could 
hint at the cellular compartment involved in altered APP processing (Lee et al., 2003). 
We hypothesize that TUDCA may modulate APP processing through the alteration of 
cellular cholesterol content or membrane fluidity, which would alter lipid raft content 
and thus APP trafficking and subcellular co-location with BACE1 (Marquer et al., 2011).  
Moreover, we intend to evaluate the effect of TUDCA on PI3K activation, a 
heterogeneous group of related kinases that regulate vesicular trafficking and alter 
APP metabolism.  For this purpose, several approaches could be employed to identify 
the PI3K isoform possibly involved in APP processing, including different 
concentrations of the PI3K inhibitor wortmannin, which inhibits different PI3K isoforms 
depending on their subcellular location (Petanceska and Gandy, 1999), and small 
interference RNA approaches designed to downregulate the various isoforms of both 
the regulatory and catalytic subunits of PI3K.  Other downstream targets of PI3K/Akt 
signalling implicated in AD could also be evaluated, especially mTOR.   
Other possible way for TUDCA mode of action may rely on its anti-inflammatory 
properties. It would be interesting to further characterize the reactive phenotype of 
microglia beyond the pro-inflammatory cytokines tested in this study, focusing on M1 
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and M2 activation markers (Mandrekar-Colucci and Landreth, 2010; Meraz-Rios et al., 
2013).  Moreover, alterations in microglial phenotypic activation can lead to different Aβ 
clearance strategies, which could be determined by co-immunostaining for Aβ and a 
microglial marker. Also, the levels of Aβ-degrading enzymes insulysin, neprilysin and 
matrix metalloproteinase 9 should be assessed to study extracellular Aβ degradation 
(Hickman et al., 2008).  Finally, GSK3β is a key mediator in glial activation, and further 
studies should be designed in order to dissect the role of TUDCA-dependent 
modulation of GSK3β and downstream inflammation-related pathways in both 
microglial and astroglial cultures exposed to several aggregated forms of Aβ.  Co-
cultures containing glial and neuronal cells could also be used to study possible cellular 
interactions and/or secretion of altered extracellular signalling molecules (Koistinaho et 
al., 2011; Ko et al., 2014). 
The anti-apoptotic properties of TUDCA in AD remain to be studied in vivo, 
since the AD mouse model used in this study does not present neuronal loss at the 
time studied (10 months of age).  In this regard, administration of TUDCA until later 
time points, during which neuron loss is detected in the dentate gyrus, would allow for 
the evaluation of the effect of TUDCA on Aβ-mediated apoptosis.  Also, other AD 
mouse models could be engaged in this objective, such as the APPSL/PS1KI double-
transgenic mouse model, which is characterized by plaque deposition at 2 months of 
age, as well as high levels of intraneuronal Aβ, which correlates with elevated neuronal 
death in AD mouse models (Casas et al., 2004; Wirths and Bayer, 2010). Importantly, 
this transgenic model displays massive neuronal loss in the hippocampus at 6 months, 
along with memory deficits and synaptic dysfunction (Casas et al., 2004).  Additionally, 
this AD mouse model could also be used to study the effect of TUDCA on 
mitochondrial dysfunction following Aβ accumulation inside this organelle, due to the 
presence of high intraneuronal Aβ levels of Aβ intraneuronally.  Finally, double mutant 
APP/tau transgenic mice would also constitute an interesting approach, due to the 
significant neuronal loss observed at 9 months of age, the age of onset of amyloid 
deposition (Ribe et al., 2005). The added value of this model is the strong development 
of neurofibrillary degeneration features, which would allow for the study of TUDCA-
dependent downregulation of GSK3β in the context of pathogenic tau 
hyperphosphorylation. 
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Finally, there are several pathological mechanisms in AD that span most 
neurodegenerative disorders, such as protein aggregation, neuronal death, 
mitochondrial dysfunction, oxidative stress and, specially, chronic neuroinflammation.  
Importantly, TUDCA stands as a promising agent capable of targeting several of these 
common pathophysiologic pathways shared among neurodegenerative diseases, 
which are desperately lacking appropriate therapies. 
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